[{"article": "\"First, I think it's very important that we investigate potential new therapies, and that we shouldn't be dissuaded from doing that just because something can be misused,\" he said.\nThis effect, the Bedi and his team suggested, could help people improve their social skills by shielding them from the negative emotions of others.\n\"More controlled research is needed to establish whether MDMA can safely and effectively add to psychotherapy for some conditions and, if so, what the mechanisms of these effects are,\" Bedi said.\nThe U.S. National Institute on Drug Abuse has more on MDMA.\nDr. Michael Mithoefer, author of the earlier study on MDMA and PTSD, also urged further exploration of the medicinal potential of the drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said that the drug \u201cmight impair a person\u2019s perceptive abilities and thus prompt risk-taking.\u201d\u00a0 Is that the only known risk of taking MDMA?", "answer": 0}, {"article": "\"This represents their average intake of fatty acids, not just a snapshot,\" Tan said.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\nBrain scans also showed signs of less blood supply in the brains of people with the lowest omega-3 levels.\nA previous study in which participants filled out food surveys found decreased risk of vascular brain problems among those who ate at least three servings of fish a week.\nThe study, published in the Feb. 28 issue of the journal Neurology, did not prove that omega-3 fatty acids prevent mental decline, merely that there may be an association between consumption of fatty acids and brain health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of eating fish are not in question, although there is some concern that certain species high in mercury can be harmful for pregnant women and children.", "answer": 2}, {"article": "To place an electronic embedded link to this study in your story This link will be live at the embargo time: http://jamanetwork.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nA comparison between less-expensive, over-the-counter hearing assistance devices and a conventional hearing aid found that some of these devices were associated with improvements in hearing similar to the hearing aid, according to a study published by JAMA.\nPresently, hearing aids can only be purchased in the United States through a licensed professional, with an average cost of $4,700 for two hearing aids (uncovered by Medicare).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release should have mentioned the potential harms of these devices compared to hearing aids so people have the full picture when considering their potential. One problem is that less expensive PSAPs don\u2019t selectively amplify speech, which could conceivably worsen hearing loss by blasting too loud and broad a range of sound.", "answer": 0}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\nBut it improves the ability to diagnose prostate cancer, Groskopf says.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of any possible harms such as diagnosing prostate cancers that won\u2019t affect the health of the individuals or missing prostate cancers that should have been treated. ", "answer": 0}, {"article": "Trachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.\nThis is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.\n\"Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.\"\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\nCo-author and McMaster PhD student, Steven Liang, explains, \"not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the release. Did any of the mice die or develop sterility or pelvic inflammatory disease?", "answer": 0}, {"article": "The panel suggests that heart patients be screened by first asking two standard questions: In the past two weeks, have you had little interest or pleasure in doing things?\n\u201cI know we can do more.\u201d\n\nAlthough there\u2019s no direct evidence that heart patients who are screened fare better, depression can result in poorer outcomes and a poorer quality of life, the panel said.\nPsychiatrist Michelle Riba said the statement\u2019s emphasis on frequent screening is important.\nIf depression is indicated, the patient may need to see a professional qualified in treating depression, the panel said, adding that treatment options include antidepressants, seeing a psychotherapist and exercise.\n\u201cWhat you want to see in a particular patient is how they do over time,\u201d said Riba, past president of the American Psychiatric Association, which has endorsed the heart association\u2019s recommendations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any possible downsides of depression screening. While there are few risks, some of the harms could include: missing cases of mild depression, stigma,\u00a0mislabeling situational stress as an illness, not to mention barriers and difficulties involved in getting the appropriate follow-up care once diagnosed.", "answer": 0}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While it\u2019s hard to imagine harms from spitting in a cup, the story does bring up the possibility that patients\u00a0might request the test even though they show no signs of being at risk for Alzheimer\u2019s, and as with any tests, the risk of false positives is always present. The story meets our standard here. Another issue that could have been raised pertains to screening for a disease for which we do not have great treatments, and the harm that can occur when one is told they will get Alzheimer\u2019s disease and can\u2019t do much about it.", "answer": 1}, {"article": "Industry analysts have estimated that 10 to 15 percent of Americans with Type 1 diabetes \u2014 perhaps 400,000 of them \u2014 use either a continuous glucose monitor or an insulin pump, or in some cases both.\nEven so, Dr. Kowalski said, using separate devices that are not designed to work in concert poses limits to treatment, particularly overnight.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\nIndeed, even if device makers are able to develop fully automated prototypes of combination systems, they are likely to face regulatory hurdles, analysts said, and would have to factor in product liability concerns.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The Times waited until the last 3 paragraphs of an 1,100-word story to hint\u00a0that an automated system could deliver unsafe doses of insulin. It isn\u2019t until the last sentence that\u00a0we learn that the system would need to be \"exquisitely reliable\" in order to be safe. We feel the story should have raised these issues earlier and that it could have done more to emphasize just how difficult it\u00a0will be\u00a0for any device to calculate insulin requirements on the fly. Insulin dosing\u00a0is affected by\u00a0factors\u00a0ranging from how much a\u00a0person has exercised to what\u00a0and how much they have eaten. It\u2019s conceivable that technology can account for all of these variables,\u00a0but there are a lot ways things\u00a0could go wrong, with potentially deadly results. It\u2019s a close call, but\u00a0we don\u2019t feel the\u00a0story\u00a0did enough to call attention to these issues.\u00a0", "answer": 0}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article focuses on why many doctors now recommend cognitive behavioral therapy rather than drugs as the first-line treatment for insomnia. As such, it does an excellent job of laying out all the negative potential side effects of anti-insomnia drugs, both prescription and over-the-counter. Given the seriousness of these potential harms \u2013 including fatigue, sleep-walking and -eating, impaired balance and increased risks of falls and motor vehicle accidents and possibly even dementia \u2013 this careful discussion of harms\u00a0provides a valuable public service. Cognitive behavioral therapy does not appear to cause any harm, a point the story might have made more clearly, especially given that it describes the benefits as lasting for \u201cup to two years,\u201d which could lead some readers to assume that CBT stops working after a relatively short time. Nonetheless, overall, the article is more than adequate in its discussion of the harms of the two approaches.", "answer": 1}, {"article": "In the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\nAnother device is being developed by scientists at the Helmholtz-Institute for Biomedical Engineering at the University of Aachen in Germany.\nThe device was developed over 15 years by a team that included Alain F. Carpentier, the French surgeon-scientist who, along with Albert Starr, received the 2007 Albert Lasker Award for Clinical Medical Research.\nIts device, powered by a small air compressor that can be carried in a backpack, has been implanted in more than 800 patients as a bridge before transplant.\nImplanted in the patient\u2019s chest after the diseased heart is removed, it uses information gleaned from sensors to mimic the activity of the natural organ.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 something that must be discussed with any artificial heart device. ", "answer": 0}, {"article": ".\nMore than 70 percent of patients surveyed reported moderate to significant improvement in their condition.\nAfter six months, more than 18 percent of patients surveyed had stopped using opioid analgesics or had reduced their dosage.\nAfter six months of treatment, more than 93 percent of 901 respondents reported their pain dropped from a median of eight to four on a 10-point scale.\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions the \u201cmost commonly reported side effects were dizziness (9.7%) and dry mouth (7.1%).\u201d\nIt would have been useful to include this information from the study: Among the roughly 900 subjects who took the follow-up questionnaire at six months, almost one-third \u201creported at least one adverse event.\u201d For about 10 percent of these subjects, they reported this adverse event as a 7 out of 10 on the severity scale.", "answer": 1}, {"article": "Of those, 25 had been admitted with a primary diagnosis of \"acute decompensated heart failure\" while another 16 patients had shown no signs of heart failure but did have other cardiovascular issues.\nDr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that if further research were able to establish its effectiveness, a breath-driven tool for identifying heart failure would be a helpful diagnostic innovation -- but more so in a doctor's office or clinic than in the hospital.\nThis study is really a proof of concept.\n\"But I would say it would be perhaps more helpful for primary care physicians in an outpatient setting, because that is where it's most challenging to identify heart failure.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story misses the mark here. It quotes a researcher saying \u201cthere is no risk involved.\u201d Even if there is no direct physical harm from breathing into a testing device, there could be substantial harm caused by actions based on the test results\u2026 including unnecessary hospitalizations and treatments or, conversely, delays in potentially beneficial treatments.", "answer": 0}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\n\u201c\n\nAmericans may not be used to eating avocado but Kris-Etherton says it\u2019s easy to add.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\nJust an avocado a day can significantly lower your cholesterol and reduce the risk of heart disease, a new study shows.\n\u201cWe need to focus on getting people to eat a heart-healthy diet that includes avocados and other nutrient-rich food sources of better fats,\u201d Kris-Etherton said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explicitly states that \u201ctoo much of a good thing can be harmful,\u201d explaining that avocados are high in calories. The story quotes a researcher associated with the study as saying that people should not simply add avocados to their current diets, but find a way to incorporate the avocado into their diets without increasing overall calorie consumption. That\u2019s the best discussion of this issue that we\u2019ve seen in any of the four stories we reviewed on this topic.", "answer": 1}, {"article": "Dr Webster added: \"Patients are brought back at frequent intervals to see if they are meeting their targets with multiple visits required to tailor their treatments and dosage.\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nAt six months, 83 percent of participants in the Triple Pill group were still receiving the combination pill compared to the majority of patients in the usual-care group still receiving only one and only one third receiving two or more blood-pressure-lowering drugs.\nCompared with patients receiving usual care, a significantly higher proportion of patients receiving the Triple Pill achieved their target blood pressure of 140/90 or less (with lower targets of 130/80 for patients with diabetes or chronic kidney disease).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "One of the goals of the approach using reduced dosage is to reduce the likelihood of side effects, but the side\u00a0 effects reported in the study were not mentioned in the news release, and include:\nOverall, 419 adverse events in 255 patients (about 38% for the triple pill and 35% for usual care)\nOf note, both groups experienced similar rates of musculoskeletal pain (roughly 7%), but the triple pill group had much more dizziness and fainting (5.2% vs. 2.8%) as well.\nIt should have been mentioned that combination antihypertensive (blood pressure lowering) medications are well known to have dozens of \u201cmajor\u201d drug interactions, and can also cause swelling and metabolic disturbances.", "answer": 0}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the newer technology may result in over treatment as there are more false positives with the CAD technology vs. radiologists' analysis alone. In a recent study published in the New England Journal of Medicine, there was 20% increase in biopsy rates after mammographers used the CAD software.", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\nKhandaker said that five of the 20 studies focused on one specific cytokine.\n\"We need more studies,\" he said, particularly research involving patients with depression who are inflamed but healthy to investigate the effect of these drugs on depression.\n(CNN) In the future, a new class of anti-inflammatory drugs could be used to treat depression, say University of Cambridge researchers.\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Except for a modest reference to clinical trials \u201cstill testing their efficacy and safety\u201d for human use, and a sentence saying that \u201cside effects must also be investigated,\u201d the\u00a0discussion of harms in this story would leave readers with the impression that these drugs don\u2019t have any notable, already-well-known side effects. But they do.\nA quick check of one of the drugs (etanercept) for example, currently prescribed for some autoimmune conditions, notes that serious side effects may include heart failure, lethal blood disorders and serious infections brought on by the suppression of the immune system by way of reductions in inflammation.\nSeeking the input of an independent source to discuss these harms and risks as they compare to standard antidepressant treatment would have been helpful, too.", "answer": 0}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nSome notice it more than others, but it happens to everyone when the lenses in the eyes lose their flexibility.\nBoth of the new implants, Raindrop and KAMRA, go into only one eye.\n\u201cThere\u2019s a healing process after the inlay is put in that requires eye drops be put in on a daily basis for around three months,\" says Hamilton.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does include an important sentence about how all surgery has risks. Here is that sentence.\n\u201cAny time you do surgery there is a risk of infection\u2014about one in 2,000,\u201d Hamilton says. \u201cAnd an infection in the cornea can cause scarring that can affect your vision.\u201d\nBut we wish the story had included the entire context for a patient considering one of two implants mentioned: What were the measured rates of side effects in the research? The story mentions that because the implants only correct vision for near objects in one eye, the other eye sometimes has to be operated on to give it perfect\u00a0distance\u00a0vision. We also wanted to know more about the impact of having two eyes with grossly different visual function.", "answer": 1}, {"article": "The children were instructed to do an hour per day of near-vision activities such as homework or computer work.\nWhile some previous research has found acupuncture for lazy eye effective, the researchers couldn't find a study that directly compared acupuncture with conventional treatments such as patching.\n''Acupuncture could potentially become an alternative treatment to occlusion [patching] therapy for ambylopia [lazy eye], the researchers write.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nAt 15 weeks, visual acuity with eyeglasses improved by about 1.8 lines on the vision chart in the patched eyes and 2.3 lines in those who had acupuncture.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This study did not report significant adverse effects with either the patch or with acupuncture. In our view, however, this\u00a0does not absolve the story from at least mentioning\u00a0the potential for harm with\u00a0both treatments.\u00a0The patch, for example,\u00a0has the potential to cause new onset amblyopia in the stronger eye.\u00a0And\u00a0acupuncture might be painful, cause infections\u00a0(though rarely), and disrupt a child\u2019s education due to the need for frequent treatments.", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While harms weren\u2019t quantified, we can accept that given the clear and concise summary of what\u2019s been shown in studies so far.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\nOf the initial 19,066 participants with a negative initial LDCT scan, 444 (2 percent) were diagnosed with lung cancer at the time of the last available follow-up.\nThe incidence of lung cancer at the first screen among those who were initially negative was 0.34 percent, compared to 1 percent of patients who were diagnosed during the baseline screening.\nThe researchers determined that eliminating the first annual screening after the initial negative test might have resulted in, at most, an additional 28 lung cancer deaths in the LDCT group (186 vs. 212 deaths per 100,000 per years) over the course of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Excessive radiation exposure and risk of false positives were both mentioned.", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention the risks of breast reduction surgery, which are considerable: infection, bleeding, blood clots, nerve and muscle damage, plus the risks associated with anesthesia. \nFurther, the story fails to mention a risk of great importance to younger women: inability to breastfeed.\u00a0 ", "answer": 0}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\nThis implies the improvement may \"have more to do with the therapeutic effect of touch than the actual therapy itself,\" Dr. Edzard Ernst, of the department of complementary medicine at Peninsula Medical School, Universities of Exeter and Plymouth, in the United Kingdom, and colleagues wrote in the report.\n\"The notion that any form of complementary and alternative medicine is effective for infantile colic currently is not supported from the evidence from the included randomized clinical trials,\" the researchers from the United Kingdom wrote.\nBut because fennel extract, certain herbal teas and sugar water are generally safe, and because the research does suggest babies may benefit, pediatricians said they would feel comfortable recommending them to parents.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not quantify the potential harms, but it makes it clear that the remedies most often used by parents have no significant side effects. It says, \u201cBut because fennel extract, certain herbal teas and sugar water are generally safe, and because the research does suggest babies may benefit, pediatricians said they would feel comfortable recommending them to parents. \u2018It\u2019s reasonable for parents to consider those kinds of interventions for which there is some suggestion of benefit but no known risks,\u2019 said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at Steven and Alexandra Cohen Children\u2019s Medical Center of New York.\u201d", "answer": 1}, {"article": "Second, the DRCR Network study is the first multi-center, randomized clinical trial to show how ranibizumab and the laser work together to improve treatment,\" Williams said.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nThe study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.\nBut researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.\nThe study of 691 patients with DME found that 50 percent of those who received Lucentis eye injections, plus laser treatment if necessary, had substantial improvement in vision one year after treatment, compared with 28 percent of patients who received laser treatment alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None discussed.\u00a0 The NYT reported: \"About 1 percent of those getting Lucentis injections suffered an inflammation of the eye from an infection.\"", "answer": 0}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nDr. High is listed as a co-author of the report because her laboratory helped monitor the patients and provided proof for regulators that the virus would not insert its human gene into the patients\u2019 sperm and make the change hereditary.\nHigh of Children\u2019s Hospital of Philadelphia, said the new therapy had worked because the delivery virus had been made more efficient and because the research team had treated the patients with steroids to suppress immune system attacks on the virus.\nDr. Nathwani and his team reported that they treated the patients by infusing the delivery virus into their veins.\nThe patients had been recruited and treated with the virus in England by a team led by Dr. Amit C. Nathwani of University College London; researchers at the Children\u2019s Hospital of Philadelphia monitored their immune reactions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions serious problems with other delivery viruses and that liver cancer had been observed in mouse studies.\u00a0 The description of the one patient\u2019s decline \u2013 and the fact that he can\u2019t be injected again with the same virus \u201cbecause his immune system is now primed to attack it\u201d was also important.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "By greatly overstating the proportion of patients at risk of heart valve disease in the large UK cohort study, the news article fails to provide balanced information about the frequency and seriousness of harms. (See \u201cDisease mongering\u201d above.) Nevertheless, the two research studies taken together reaffirm the strongly held suspicion that these drugs have the potential for causing valvular disorders.\u00a0", "answer": 0}, {"article": "Between 12% and 20% of women in the 35 countries in the Organisation for Economic Co-operation and Development suffer from perinatal depression, and 20-35% in poorer countries.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\nCognitive behavioural therapy has significant positive effects on a mother\u2019s mental health, income, employment and parenting skills even seven years after the birth of the child, according to the first study of its kind.\nWhile studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not make any statement on the risks or drawbacks of this intervention. However, given the relatively low-risk profile of cognitive-behavioral therapy, we\u2019ll rate this N/A.", "answer": 2}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\n\u201cThis is a novel finding,\u201d Dr. Vezzani said in an interview.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\n\u201cGiving a medication that could treat the epilepsy, as opposed to treating the seizure, would be absolutely novel,\u201d Dr. French said.\nAlthough they give many epileptics a better quality of life, they do not affect the course of the disease, only its symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Very low in the story, it mentions harms, saying, \u201cBut there are dangers to this approach. Steroids \u2014 potent anti-inflammatories that some doctors are using for experimental treatments \u2014 can have harmful long-term side effects. And it remains unclear whether inflammation might be implicated in all forms of epilepsy or which patients might benefit from anti-inflammatory treatment.\u201d", "answer": 1}, {"article": "\u201cIt yielded no benefit,\u201d he said.\n\u201cIf we can even slightly lower their average blood sugar with metformin,\u201d Wilkin said, \u201cI believe we can have a big benefit on their risk of developing Type 1.\u201d\n\nDespite all these potential benefits of metformin \u2014 and despite a recommendation from the American Diabetes Association that it be tried before any other drug for newly diagnosed Type 2 diabetics \u2014 a recent study found that only about half of all such people get metformin as their first prescribed medication.\nThe author of the study, Niteesh Choudhry, an associate professor of medicine at Harvard Medical School, also found that newly diagnosed Type 2 diabetics who start on metformin are the least likely to need an additional diabetes drug later.\nThe question is whether the rate-of-living theory is operational in mammals.\u201d\n\nPollak says that none of the most exciting possible benefits for the drug have yet been proved in randomized clinical trials of non-diabetics.\nFor now, the evidence suggesting benefits is limited to large studies of diabetics that have found, on average that those who take metformin tend to have lower rates of cancer, heart disease and dementia, and to live longer overall than those who take other drugs for diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The implication of this story is that metformin may help others besides those with type 2 diabetes. Other groups mentioned in the piece include those with type 1 diabetes, polycystic ovary disease, dementia, cancer and simply those who are aging (ie. everyone). The only side effect mentioned is stomach upset. So one could arguably conclude that everyone should be on this medicine. Not mentioned are the potentially dangerous side effects of metformin. Specifically it should not be given to those with acute or chronic kidney disease (a condition that commonly goes undetected). It can induce lactic acidosis which can be serious, even life-threatening. This is so well known that metformin is commonly held when patients are admitted to the hospital with an acute illness.", "answer": 0}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s mentioned:\n\u201cNitrous comes with some caveats. It can cause nausea and dizziness. It also interacts with vitamin B12, so women with a deficiency of the nutrient shouldn\u2019t use the gas \u2026 but studies \u2014 and generations of use worldwide \u2014 have not found complications or long-term problems.\u201d\nThis is enough for a satisfactory rating. However, we\u2019re left asking: where\u2019s the evidence? Some research findings to support a midwife\u2019s statement in a review that nitrous is \u201csafe for the mother, fetus, and neonate\u201d would be salient for many expecting mothers.\nIt\u2019s also important to point out that if you Google \u201cnitrous oxide & harms\u201d you will come across a much larger list of harms, some of them quite ominous. But most of these occur in the setting of the prolonged and extensive abuse of recreational nitrous oxide (aka \u201cwhippets\u201d). But, presumably, the obstetric use of nitrous \u2014 which is a brief exposure to limited doses \u2014 would pose much less risk. Mentioning this would help clarify things.", "answer": 1}, {"article": "\"We're trying to make it simpler, but we don't want to lose the efficacy,\" he said.\nBredesen said that his team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\nJames E. Galvin, M.D., M.P.H., a professor of clinical biomedical science at FAU's Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing, who was not involved in the study, agreed that personalized approaches such as the MEND protocol are the types of approaches needed for this disease going forward.\nOne participant from the 2014 study, who had been diagnosed with late-stage Alzheimer's, did not show improvements with the protocol.\nBredesen noted, too, that the MEND protocol was suitable for patients in the early stages of Alzheimer's.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential risks of any aspect of the protocol. It does say that MEND \u201crequires the use of supplements which are not well studied and do not require FDA approval.\u201d It does not mention what supplements these are and what risk they might present.\nAlso, the authors of the study suggest testing for the\u00a0APOE\u00a0gene,\u00a0and that those with a certain gene variance be treated with this protocol. The majority of those with the variance, though, will not get Alzheimer\u2019s, so this is potential overtreatment and exposure to harms for little-to-no benefit. Several of the 10 people in the study did not complete the protocol, and some of that might have been due to adverse effects, but that was not mentioned.", "answer": 0}, {"article": "\u201cThis isn\u2019t a magic bullet.\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nMany patients described a profound experience, he said, and appeared to undergo a shift in the way they perceived the world.\nCarhart-Harris said no serious side effects were reported during the study, although all volunteers said they were slightly anxious before and during initial drug administration.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential risks\u00a0of using hallucinogenic drugs, including anxiety and paranoia, are mentioned.\nThe story also could have mentioned that inducing hallucinosis can result in other self-harm and is potentially much more dangerous.", "answer": 1}, {"article": "A study published in this month's issue of the Archives of Neurology found that the diet might protect against blood-vessel damage in the brain, reducing the risks of stroke and memory loss.\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of harms and we\u2019re not sure what they would be.", "answer": 2}, {"article": "They included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\nFuture research might focus on interventions that could help diffuse these frustrations, the paper noted.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\nIn analyzing the recordings, Williams identified 10 communication patterns that caregiving spouses used to connect with their partners and show affection.\nThe couples, who were recruited from a day program for people with memory disorders and their spouses, were receiving coaching in communication, with caregivers learning to listen, to avoid arguing, to not treat their spouse like a child.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this category as Not Applicable since the study, and the story, were observational. The authors\u2019 conclusions are based on how they interpreted the actions of caregivers during conversations with spouses that seemed to result in more favorable communications.", "answer": 2}, {"article": "Dementia affects about 50 million people worldwide, with 10 million new cases occurring every year.\nThey found that cognitive impairment markedly improved in mice with conditions similar to vascular dementia and Alzheimer's disease when LIPUS was applied to the whole brain three times a day for 20 minutes each time.\nFocusing LIPUS treatment on a region in the brain called the hippocampus, which is involved in memory, has also been found to improve dementia in mice, but the details of how it does this need to be more fully investigated.\nThe team, led by cardiologist Hiroaki Shimokawa, found that applying low-intensity pulsed ultrasound (LIPUS) to the whole brain of the mice improved blood vessel formation and nerve cell regeneration without having obvious side effects.\nThe mice with a condition simulating Alzheimer's disease in humans received 11 LIPUS treatments over a period of three months.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes there were no \u201cobvious side effects\u201d in the mice. But we really have no idea if there would be harms in humans or even primate models. Ultrasound applied to the head has been shown to warm up tissues in the brain, though what possible harm this may cause is uncertain. High-energy frequencies (greater than those used by LIPUS) can cause a raft of detrimental effects, though, including temporary suppression of brain cell function and brain damage.\nThe study goes into further detail on harms in the mice models by stating \u201cLIPUS-treated mice showed no signs of cramps, paralysis, cerebral hemorrhage, hypothermia, hyperthermia, or increased mortality compared with control mice.\u201d However, you can\u2019t ask a mouse how it feels, and it\u2019s uncertain how often LIPUS may be needed in a mouse, let alone a person, to reap any potential benefits.", "answer": 0}, {"article": "\u201cDr.\n\u201cThis variation of a standard technique used during breast reconstruction will revolutionize the post-operative recovery in patients who meet certain criteria for the procedure,\u201d notes Dr. Small.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\nValley was the first hospital in northern New Jersey where an innovative technique \u2013 called pre-pectoral placement of a tissue expander -- was utilized during breast reconstruction surgery following a mastectomy.\nNewswise \u2014 The breast surgery and reconstructive team at The Valley Hospital in Ridgewood, NJ, is taking the lead in providing new and progressive advances in breast cancer surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As a 2013 New York Times Well blog post highlights, about one-in-four nipple-sparing surgeries (promoted by\u00a0this release) lead to dead tissue \u201cin the areola or in nearby skin\u201d \u2014 and additional surgeries to remove that dead tissue.\nThe risks or necessity\u00a0of mastectomy and reconstructive breast surgery aren\u2019t mentioned, either. Mastectomies (as compared to lumpectomies or avoiding surgery altogether) may not lead to better outcomes for many women. Also, implants can leak, cause infections, and lead to other complications. We\u2019re also not told how radiation and chemotherapy \u2014 two extremely common treatments in conjunction with breast cancer surgeries \u2014 affect results.\nThe one saving grace of this release is its last word, which makes a case for approaching each woman\u2019s diagnosis and treatment on an individual basis.", "answer": 0}, {"article": "Bochner and his colleagues Drs.\n\"It almost completely knocked out the patients' skin test and blood cell allergic reactivity,\" said senior author Dr. Bruce Bochner, the Samuel M. Feinberg Professor of Medicine at Northwestern University Feinberg School of Medicine.\nAnne Marie Singh and Melanie Dispenza are now testing how successful the drug is at targeting allergies to food, such as tree nuts and peanuts.\nThis FDA-approved drug, ibrutinib, is currently on the market as a successful and less-toxic alternative to chemotherapy for patients with chronic lymphocytic leukemia and mantle cell lymphoma.\nThe cancer patients who were allergic to allergens such as cat dander and ragweed saw their allergic skin test reactivity reduced by 80 to 90 percent in one week, and this persisted with continued use of the drug for at least one to two months.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Readers of this release get no alert that the labeling of ibrutinib warns of potentially life-threatening bleeding, infections, decreased blood cell counts, heart rhythm problems and also that patients commonly suffer diarrhea. The release not only fails to mention any of these risks and side effects, it projects an unsupported aura of safety by describing the drug as an FDA-approved \u201csuccessful and less-toxic alternative to chemotherapy.\u201d", "answer": 0}, {"article": "The Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nScientists have found a marker that can indicate your likelihood of suffering from rheumatoid arthritis (RA) even sixteen years before the condition takes effect.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\nFurthermore, current tests for rheumatoid arthritis are limited in their ability to diagnose disease in different patients.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release briefly notes that the test carries a very low rate of false positives. However, the harms from screening tests are well-known. A false positive can result in additional tests, unnecessary treatment, anxiety and financial strains. A major concern is using the test in asymptomatic individuals who may be at risk for future development of symptoms due to rheumatoid arthritis. If the test isn\u2019t 100% specific, it means we\u2019re telling some patients who are otherwise fine that they\u2019re going to develop something bad in the future \u2013 when in fact they won\u2019t. Oops! Second, it isn\u2019t clear that treating such asymptomatic patients may benefit them long-term. Remember the drugs for rheumatoid arthritis all have side effects \u2013 some of which can be quite serious. These potential harms are not mentioned at all.", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated:\u00a0 \u201cThe agency says patients treated with the new system experienced a slightly higher incidence of neurological side effects, including convulsions and headaches, than patients receiving chemotherapy.\u201d\nWhat does slightly higher incidence actually mean?\nWhat is the baseline incidence \u2013 in actual numbers?\nAnd how much higher was the incidence with the new system?\nGive the numbers and let readers/consumers decide what\u2019s \u201cslightly higher\u201d and what that might mean in their own lives.", "answer": 0}, {"article": "More than 25 million people in the United States and about 2.5 million Canadians suffer from chronic rhinosinusitis, or sinus infection, and experience compromised quality of life.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\nSince the impact was less than in previous studies that had used more intensive coaching about nasal irrigation, the authors suggest that further research is needed to understand how much coaching of patients is required.\nResearchers from the United Kingdom conducted a randomized controlled trial on the effectiveness of advice from primary care physicians to use nasal irrigation and/or steam inhalation for chronic sinusitis.\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms. While considered to be safe, there are risks to nasal irrigation that include a potential failure to seek appropriate medical attention as well as infection, headache and nosebleed, according this consumer fact sheet by the FDA.", "answer": 0}, {"article": "\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\nThe authors suggest the score can be useful for standardizing diagnoses and improving safety.\nAn international team of researchers has developed a simple laboratory score that is safer and faster at diagnosing patients who visit the emergency department with heart attack symptoms.\nA negative (or low-risk) clinical chemistry score at emergency department presentation missed only one of these events compared with up to 25 missed heart attacks/death when using a high-sensitivity cardiac troponin test alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The text is specific about the number of heart attacks that would have been missed by the scoring system (1 out of 727) in this population of 4000+ patients who went to emergency rooms with possible symptoms.\nThis indicates a high sensitivity, which is good because it means that the test is not missing people likely to have a heart attack or die within 30 days. \u00a0However, the other potential harm from a diagnostic test is from false positive results \u2014 which could lead to unnecessary hospitalizations and treatments. \u00a0This statistic is not addressed in the release, though it is presented in the study.", "answer": 1}, {"article": "But it is also relevant to anyone who takes their weight management seriously and wants to stay lean and healthy.\"\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nThis finding is important for people who are trying to lose weight, including those suffering from metabolic syndrome and/or type 2 diabetes.\nIn addition, reducing intramuscular fat could help improve muscular strength and mobility, particularly in older people with diabetes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release may encourage people to embark on a vegetarian diet without enough knowledge of the potential downsides. Without careful meal planning, people on vegetarian diets risk not getting enough protein, vitamin B-12, iron, zinc, omega-3 fatty acids. A brief mention of these challenges would have been helpful.", "answer": 0}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\nMSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine's inventions to life.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We found just one comment.\u00a0Excerpt: \u201cThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\u201d\nEach drug shows different efficacy, so we\u2019re not sure how this was established. Also, it\u2019s standard to track\u00a0adverse events in trials. For this one, what adverse events did the researchers find? We\u2019re not told.", "answer": 0}, {"article": "Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results.\n\"Clinical trials revealed that PPF can cross the blood-brain barrier, and has minimal side effects,\" Dr. Tran said.\n\"PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients.\"\nThis study was funded, in part, by The Ben & Catherine Ivy Foundation.\nHowever, this security system is so effective at protecting the brain that it prevents many life-saving drugs -- all but some small molecules -- from being able to treat cancer and other diseases of the brain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Not only does the release fail to mention any potential harms, it dismisses such concerns with a quote about \u201cminimal side effects.\u201d", "answer": 0}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n\u201cThe treatment of cachexia just doesn\u2019t exist.\nNewswise \u2014 Fresh thyme and oregano offer a savory touch to a tasty dish, but a University of Iowa researcher recently discovered natural compounds in the herbs that may offer a treatment for cachexia or \u201cwasting syndrome\u201d as it is more commonly known.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms from these mysterious, unnamed\u00a0compounds.\u00a0 And without their identification, readers are left clueless about any risks that might be involved. The inference is that since oregano and thyme are common, edible spices that they would present no harms once prepared in over-the counter products.", "answer": 0}, {"article": "But this is important enough and impressive enough to tell people about,\" said Robert Temple of the Food and Drug Administration, who spoke to reporters about the findings.\nExposure to ACE inhibitors early in pregnancy nearly tripled the risk of birth defects, the study showed.\nThe alternatives that clinicians might want to consider are diuretics, alpha-methyldopa, some beta-blockers, and the calcium-channel blocker nifedipine, according to the FDA officials and an editorial accompanying the study.\nAll new drugs are tested on pregnant animals to see whether they cause malformations, but those tests can be misleading.\nIt's considered unethical to include pregnant women in studies of new drugs unless the medication is intended to treat pregnancy-related conditions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms to the fetus of treating a mother with an ACE inhibitor during the first trimester of pregnancy are plainly mentioned. However the risks of NOT using ACE inhibitors in some women (congestive heart failure, diabetes) are not mentioned. This study was not done in a high risk group and the risks of undertreatment may be greater in some populations. So, for example, women with diabetes and renal dysfunction or those with congestive heart failure would have gotten an incomplete picture from the article.", "answer": 0}, {"article": "\u201cBut I point out that we don\u2019t yet have randomized, controlled-trials data to back it up.\nSuch findings are why she, Mowry and Pittas strongly advise people against taking more than the currently recommended upper daily limit of 4,000 IU, even though doses as high as 10,000 IU are available online and at many stores.\nThat\u2019s why there are no official recommendations yet from any medical organizations.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\n\u201cBut keep in mind, there isn\u2019t yet evidence that taking those higher amounts will confer any benefits beyond the recommended daily allotment of 600 to 800 IU.\u201d\n\nSome studies, she noted, have even found evidence that very high levels of vitamin D circulating in the blood might be just as unhealthful as very low levels.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Research has shown risks from high levels of vitamin D. We were glad the story included the following:\n\u201cA 2014 study, for instance, found that people with the highest levels of vitamin D in their blood (more than 60 nanograms per milliliter) were significantly more likely to die in the three months following a hospitalization as were people whose levels were between 30 and 49.9 ng/mL.\u201d\nAnother possible harm that the story could have examined is people downing pills and thinking they have \u201cprevented\u201d some future problem. Does taking a vitamin pill reassure them and delay or forestall established preventive measures such as diet and exercise, known to help prevent type 2 diabetes and heart disease?", "answer": 1}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nThe initial clinical trials established the safety of the test for patients.\nIt uses a specially developed fluorescent marker which attaches to cell proteins when injected into patients.\nThe technique developed is called DARC, which stands for detection of apoptosing retinal cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states only that the initial trials established the safety of the test in patients. The published research says that \u201cANX776 [the florescent marker or dye injected into patients] was found to be safe and well-tolerated with no serious adverse events, and a short half-life (10\u201336 min).\u201d If there were non-serious side effects, readers deserve to know what they are.", "answer": 0}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nInfants in the partial treatment group fared better than untreated infants.\nInfants in the complete treatment group fared best.\nThe study followed the infants from birth to 18 to 22 months of age and measured survival and brain and nervous system outcomes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Every intervention carries risks, and antenatal steroid therapy is no exception. Although this therapy is generally deemed to be safe, some studies have reported undesired effects on the mother\u2019s immune system and metabolism, as well as reduction of fetal heart rate and breathing movements. A multiple course of antenatal steroids might even slow fetal intrauterine growth and lower neonatal birth weight.\nSince harms were not addressed, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "The American Heart Association has more on heart failure.\nResults were even more heartening at higher doses, where participants had an 88 percent decrease in risk for death, cardiac transplant, hospitalizations and other outcomes, the study authors said.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\nThe enzyme regulates calcium cycling, which, in turn, is involved in how well the heart contracts, the researchers said.\nFor this phase 2 study, 39 patients with advanced heart failure were randomly chosen to receive either the gene therapy (through cardiac catheterization) or a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms. Even though the researchers said in their meeting abstract that the therapy had \u201can excellent safety profile\u201d in this trial, the story should have pointed out that patients have been harmed and some have died during experiments using other types of gene therapy.", "answer": 0}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\nNumbness and pain stemming from nerve damage were the most common adverse event connected to eribulin that led women to drop out of the study (24, or 5 percent).\nThe researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag.\nWhile the story points out the most common side effects, fatigue and depletion of white blood cells, occurred in both study groups, readers aren\u2019t given any sense of how common these were.\u00a0 In fact, they were quite common: these side effects occurred in 54% of those on eribulin and 40% of patients in the treatment of physician\u2019s choice group.\u00a0 This is why we expect stories to quantify harms.\nTo its credit, the article does note that the most common adverse event that caused women to drop out of the eribulin arm was neuropathy, or numbness and pain caused by nerve damage \u2013 and it notes a 5% study drop out rate.", "answer": 0}, {"article": "Research has shown that our unhealthy eating habits and sedentary lifestyles are playing a major role in the development of lifestyle-related metabolic diseases such as diabetes, heart disease and obesity.\nThe fasting regime helped lower fat build-up in the white fat by increasing the brown-like fat (involved in burning energy and producing body heat) of mice on the high fat diet.\nThe lower body weight of the mice in the fasting group was not the only effect.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\nThe recurring regimen saw the animals being fed for two days, followed by one day without anything to eat.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any potential harms that could exist for intermittent fasting.", "answer": 0}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said reported side effects included reactions at the sites of the infusion and swelling around blood vessels observed with brain imaging, and that the companies \u201csaid they plan to present the results in detail at [an] academic conference.\u201d\nThe story could have been clearer on how common these side effects are and how serious they were. According to the companies\u2019 news release, infusion-related reactions \u201cwere mostly mild to moderate in severity. Incidence of ARIA-E (edema) was not more than 10% in any of the treatment arms, and less than 15% in patients with \u2026 the highest dose per the study protocol safety and reporting procedures.\u201d\nThese are concerning potential harms for which no one knows the long-term consequences.", "answer": 1}, {"article": "Dr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nA team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\nIt is believed that success rates could be hindered as a result of treating all prostate cancers in the same way.\nThe team needed to eliminate the 'noise' of the genetic patterns that make individuals unique, to leave them with the patterns that indicate cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release says that unnecessary radiotherapy and surgery is harmful, but it does not explain any harms of the new tests. Although biopsies are minimally invasive, the Mayo Clinic says that prostate biopsies can cause bleeding and risk of infection.\nIn this test, the tissue was collected only from prostatectomy specimens. \u00a0Therefore, to actually be useful for preventing over treatment, the test must be assessed in biopsy specimens. \u00a0The harm would be misclassification \u2014 mistakenly telling someone that treatment is unnecessary because the tumor appears to be low-risk when in fact it\u2019s aggressive and would benefit from treatment.", "answer": 0}, {"article": "Stress tests measure the heart's response to exertion, letting doctors see or hear any disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\nThe first showdown pitting 3-D, heart-imaging exams against older stress tests atop treadmills or stationary bikes found that among 10,003 heart patients, their rates of eventually having serious heart events were the same \u2014 no matter which method doctors used to check their tickers, researchers said.\nUntil this study, doctors have been \"guessing\" which form of those two diagnostic tests is best, Douglas said.\nWhich prompts a big question: Could the use of stress tests or expensive scans become less frequent for heart patients, replaced by more watchful waiting?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential drawbacks of these interventions are not discussed. \u00a0 The press release describing this study did note potential harms of the stress tests: they were associated with more catheterizations, and nuclear stress tests were associated higher levels of radiation exposure compared with CTA. But the story did not pick up on that information. (There was also no mention of the fact, either in the story or press release, that standard exercise electrocardiography involves no radiation exposure, and would presumably be the lowest-risk option as far as radiation is concerned.)\u00a0As noted above, the only hint of possible harm that occurs is an end-of-story anecdote about an individual whose stress tests failed to signal the presence of blocked arteries.\u00a0 The inference here is that stress tests can miss diagnostic signals that CTA will find. \u00a0Oddly, the anecdote seems incongruent with the main message of the story.", "answer": 0}, {"article": "Zied is also the author, with Ruth Winter, of a book titled \"So What Can I Eat?\"\nWomen of child-bearing age are strongly encouraged to take it, because it can prevent birth defects.\nDr. Emily Senay discussed it on The Early Show Tuesday.\nOn The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\nThe magazine says small gestures by parents make big impressions, teaching enduring lessons.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms or lack of harms that are associated with adequate folic acid intake in women of child bearing age.", "answer": 0}, {"article": "CHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\nSeveral oncology experts said liquid biopsy tests like Pathway\u2019s, while exciting, still require large clinical studies proving they help people beat cancer through early detection.\nBut cancer experts say there are major differences between using such tests to screen for cancer and monitoring patients who are already known to have it.\nSeveral cancer diagnostic companies have been working on the tests, a field that has recently been joined by makers of DNA blood screening tests for fetal abnormalities after the tests detected early cancers in expectant mothers.\nAnother concern is that the tests may pick up on markers that are never destined to be cancer, something already known to occur in blood tests for prostate cancer, Kopetz said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The competing Bloomberg story gave a nod to false positives and false negatives, but Reuters really explained why these tests could lead to harms. The story says, for example, \u201cPatients might be attracted to a less-invasive test for colon cancer, but if it is less effective, it might result in more cases of colon cancer, not fewer.\u00a0Another concern is that the tests may pick up on markers that are never destined to be cancer, something already known to occur in blood tests for prostate cancer\u201d.", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports the panel believes the drug to be \u201csafe\u201d but does not describe any side effects or harms of rivastigmine. These may include nausea/upset stomach, vomitting, loss of appetite, and headaches. ", "answer": 0}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nStill, the approach offers promise to some people that other therapies can't, and has transformed the way doctors think about cancer treatment.\nWhat Belvin didn't know at the time was that a revolutionary treatment for melanoma had begun testing in clinical trials.\nAn immunologist named Jim Allison, now at the University of Texas MD Anderson Cancer Center, had figured out that if the immune system was tweaked just right, it could do a better job of killing the cancer than the usual treatments.\nAllison's treatment was still experimental, but if it worked, it had the potential to save Belvin's life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned, which is a significant oversight. We understand that this is a story about a man and his accomplishments in developing a tool to fight cancer. But to paint a full picture, you have to describe the tool. And it\u2019s impossible to discuss ipilimumab without discussing either its cost or its potential harms. The manufacturer\u2019s own website states that ipilimumab \u201ccan cause serious side effects in many parts of your body which can lead to death. These serious side effects may include: intestinal problems (colitis) that can cause tears or holes (perforation) in the intestines; liver problems (hepatitis) that can lead to liver failure; skin problems that can lead to severe skin reaction; nerve problems that can lead to paralysis; hormone gland problems (especially the pituitary, adrenal, and thyroid glands); and eye problems.\u201d\nJust as with costs of the drug, we don\u2019t expect a story to offer a thorough inventory of potential adverse health effects, but failure to acknowledge them in any way is a significant oversight \u2014 particularly when they can be this severe.", "answer": 0}, {"article": "http://jama.\nRadiologic malunion (abnormal healing of a fracture) was more common in the casting group (15 percent vs 3 percent for surgery).\nAt 6 months, casting resulted in measures of ankle function equivalent to that with surgery.\nInfection and wound breakdown were more common with surgery (10 percent vs 1 percent), as were additional operating room procedures (6 percent vs 1 percent).\nThe researchers add that close contact casting may be an appropriate treatment for older adults with unstable ankle fracture.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A release devotes a fair amount of space to harms from casting as compared with surgery:\n\u201cRadiologic malunion (abnormal healing of a fracture) was more common in the casting group (15 percent vs 3 percent for surgery). Casting required less operating room time compared with surgery. There were no significant differences in other secondary outcomes: quality of life, pain, ankle motion, mobility, and patient satisfaction.\u201d", "answer": 1}, {"article": "\"It's very stressful because you're sleep-deprived, you're not eating right ... you're working back-to-back shifts and you're trying to catch up on sleep but you can't,\" Dalechek said.\nPrevious research has shown benefits from similar web-based therapy in other settings.\nGuille said offering web-based therapy routinely to medical residents could be beneficial, if her research results are confirmed in a broader study.\nA study suggests online self-help behavior therapy could be a solution.\nThe online program included sessions about how to put feelings of stress or despair into perspective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It is hard to imagine harms associated with this approach so we will rate it as not applicable.", "answer": 2}, {"article": ".\nFurthermore, restarting therapy with the new oral anticoagulant dabigatran was associated with a lower risk of recurrent hemorrhage in these cases than the old standby drug warfarin.\nMore than 1,500 of those people suffered a major bleeding event while using one of the drugs.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\nPeople who took dabigatran after their initial bleeding event had nearly half the risk of another major bleeding event within one year compared with those who took warfarin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release deals with bleeding, which is the most concerning adverse effect of blood thinners. But there are other harms including joint pain, bruising and dizziness. Warfarin requires dietary restrictions and regular monitoring with blood tests.", "answer": 1}, {"article": "Too much insulin can cause low blood sugar (hypoglycemia), which can be life-threatening, while too little causes the serious damage of diabetes such as kidney, vision and circulation problems.\nThese results were similar to findings in children where the system extended the amount of time spent at target blood sugar levels, he added.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nSUNDAY, June 27, 2010 (HealthDay News) -- New research suggests that artificial pancreas technology can help diabetics gain greater blood sugar control overnight, even when they have eaten a big meal or had wine for dinner.\nSpeaking at the Saturday teleconference, Dr. William Tamborlane, chief of pediatric endocrinology at Yale University School of Medicine and co-chair of the Juvenile Diabetes Research Foundation's Continuous Glucose Monitoring Group, said the system only works if worn almost every day.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The investigator is quoted as saying that \"We reduced hypoglycemia by half.\" There\u2019s a dissonant choir of problems with this statement. First, it\u2019s not clear from the sentence\u2019s placement in the article if this result came in the prior study with children or in the current study with adults. (The rest of these points assume the latter.)\nSecond, the article doesn\u2019t identify the comparator group (those who just used the insulin pump), so a relative result is meaningless. So when the claim is made, \"We reduced hypoglycemia by half,\" readers should be told \"half of what?\" \nThird, the fact that they used a relative risk reduction figure, not an absolute one, is important because this study was so short and small, using relative risk reductions masks the weight (or thinness)\u00a0of the evidence, especially when we don\u2019t have the statistical significance. \nFourth, we\u2019re not sure what data the investigator\u2019s statement of reducing \"hypoglycemia by half\"\u00a0is based on. In\u00a0the\u00a0abstract, it\u2019s says that the time spent below target glucose was approximately half but\u00a0the difference was not\u00a0statistically significant, no doubt due to the small power and short duration of the study. If our interpretation is correct, the story\u2019s author has touted a benefit that\u2019s insignificant, statistically speaking.\nFifth, it should\u2019ve been clearer about what \"reduced hypoglycemia\" mean? The total time spent below target glucose range \u2014 which averaged out over the course of the study \u2014 is different than a (severe) hypoglycemic event, which some readers may read in this result. How dangerous is it to spend any time below the target range, if only temporary and possibly briefly? In other words, is it a harm or an efficacy issue? In the\u00a0abstract, we read about 1 serious case of hypoglycemia \u00a0with the insulin pump, 0 with the closed-loop system; but again, with 12 patients using each for a night, statistically we\u2019re not sure what that tells us.\u00a0\nRegardless of the true intent of this statement, and the true harms that occurred in the study, an independent analysis may have clarified such confusions.", "answer": 0}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\nThe study included patients with mild and severe disease who received stimulation in the fornix continuously for 1 year.\nNext, Lozano launched a randomized trial involving 42 patients from the US and Canada, all of whom had electrodes implanted in the fornix on both sides of the brain.\nHowever he acknowledges Lozano's results suggest that DBS to the fornix might be promising for a subgroup of patients, those being older people with less severe disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the study showed \u201cboth the surgery itself and DBS of the fornix appear safe\u201d and \u201cno serious, long-term side effects were seen in either patient group, supporting further research in the field.\u201d\nBut the story doesn\u2019t mention that 26 (61.9%) of the 42 patients in the study experienced one or more adverse effects. Five patients (11.9%) experienced one or more serious adverse effects, and four of those patients required a return to surgery.", "answer": 0}, {"article": "Every year, U.S. News & World Report asks experts to rank various diets to help the tens of millions of dieters in the United States and around the globe make informed dietary decisions that can help them achieve healthier lifestyles.\nThey also considered how easy each diet was to follow, as well as safety and nutritional value.\nThe panel of experts -- including nutritionists and doctors specializing in diabetes, heart health and weight loss -- scored each diet for short-term and long-term weight loss.\nThe Raw Food diet was also considered the most difficult diet to follow, though it was one of the top ranked weight-loss diets, the panel found.\nOn the opposite end of the list, the Whole30 diet -- a 30-day program that bans processed foods, legumes, grains, dairy, alcohol and added sugar -- ranked as the worst overall diet on the list, the new report said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of the DASH diet are negligible, so we won\u2019t ding the story for not mentioning them. We\u2019d note, however, that USN&WR\u2019s online summary of the \u201ccons\u201d of the diet include \u201cLots of grunt work\u201d and \u201csomewhat pricey.\u201d\u00a0 The implication of these drawbacks is that well-meaning people will not be able to adhere to the diet.\u00a0We would have appreciated a delve into what \u201cLots of grunt work\u201d refers to.", "answer": 2}, {"article": "With relaxation of the muscles, the distance between the vertebrae returns,\" Dr. Napoli explained.\nDr. Napoli said no patients experienced side effects after receiving the minimally invasive outpatient treatment.\nOf the 80 patients treated, 81 percent were pain free one year after a single 10-minute treatment session.\nNinety percent of the patients were able to avoid surgical treatment.\nThe single-center prospective study included 80 patients experiencing at least three months of low back pain due to a herniated disk that had not responded to conservative treatments including exercise and medication.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does mention side effects, saying, \u201cDr. Napoli said no patients experienced side effects after receiving the minimally invasive outpatient treatment.\u201d\nBut just because there were no side effects in this small study, does that mean there is no risk of such side effects for anyone? That seems like downplaying the risks. The release would have been more thorough had it mentioned that any invasive treatment such as this one carries a risk of infection.  ", "answer": 1}, {"article": "Rates are rising, in part because tanning became fashionable.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\nThere are side-effects, including fatigue, itchiness and rash.\nAbout 15 percent of these patients have what\u2019s called a complete remission, meaning there is no trace of their tumors.\nAnother 14 percent had a partial response, meaning their tumors shrank a little, compared to 9.4 percent on standard treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Side effects are described \u2014 fatigue, itchiness, and rashes \u2014 and even notes the dropout rate of 8%.", "answer": 1}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\nDr. Neil M. Bressler of Johns Hopkins University, the chairman of the group that conducted the trial, said a two-line improvement in vision would allow some people to read normal-size print or to drive again.\nBut he said there were other factors as well, like a belief that Lucentis might have been the better drug.\nThe steroid treatment did not improve eyesight more than laser therapy alone and caused side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0While the story did include the common side effect of the drug in the study, there were other potentially important complications that were not mentioned.", "answer": 1}, {"article": "http://www.\nThere are over two million cases a year in the U.S. and the lifetime risk of developing a BCC before the age of 85 years is one in five people.\nA three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT), as reported by investigators in the Journal of Investigative Dermatology.\nFor example, we have found that in superficial BCC on the lower extremities in older patients, PDT should be prescribed rather than imiquimod.\nA total of 601 patients with a superficial BCC participated in this study: 202 patients were treated with methylaminolevulinate photodynamic therapy (MAL-PDT), 198 with imiquimod cream, and 201 with fluorouracil cream.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release makes no mention of the side effects of either drug.\nThe news release does note that, between 1- and 3-year follow-up, \u201cmore recurrences were diagnosed in the fluorouracil group compared with the imiquimod group.\u201d It would have helped to know how many more recurrences.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although this story did a great job on most counts, it didn\u2019t mention potential harms of IUDs. Cramping, spotting between periods, and heavier periods are all possible side effects. The bigger issue that the story could have mentioned, though, is that IUDs don\u2019t protect against other STIs.", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\n\u201cDecompression on the West Coast is a dime a dozen, but here in the Midwest, they are almost unaware of it.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\nIt is designed for patients who have not had surgery.\nIt is less than half the cost of surgery but is rarely covered by insurance.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms of this approach. ", "answer": 0}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\nThe authors caution that given the limitations of the performance of the altona RT-PCR reference test in patients with low levels of the virus in their blood, more research is needed to assess how the new RDT will perform in patients very early in the course of EVD.\nThis new rapid diagnostic test (RDT) could cut back on the lengthy process usually required to confirm if a patient has EVD, help identify case contacts, and ultimately curb the spread of Ebola.\nEarlier test results would improve triage of patients, enabling staff to focus on those most likely to have Ebola, and reducing the opportunity for infection of non-Ebola 'suspects'.\n[1]\n\nWriting in a linked Comment, Dr Nahid Bhadelia from Boston University School of Medicine and Boston Medical Center, Boston, USA says, \"[This study] validates the accuracy of the ReEBOV RDT in patients who are well into their illness...suggesting it could be used to triage this subset of patients if RT-PCR is not available, particularly in those with a high index of clinical suspicion for a differential diagnosis...the data presented provide crucial information about the point of-care function of this rapid diagnostic test, such as ease of use, quality of samples taken at the bedside, and the concordance with venous samples...the results raise caution regarding the performance of the widely used altona RT-PCR assay, which the authors suggest might have underperformed because of laboratory specific technical and performance factors.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release explains how not having a rapid-diagnostic test could expose people who are otherwise healthy to Ebola.\u00a0But there are some less obvious harms\u00a0this release probably should have addressed. For example, there\u2019s only brief mention of how\u00a0the new test missed some early\u00a0cases of EVD. Waiting a few minutes for a result is better than hours or days, of course, but letting infected patients with a false-negative test out of quarantine is a serious concern.\u00a0It would also be useful to talk about the impact of a false-positive result (since specificity was 92%). What are the consequences of telling someone they have Ebola when they don\u2019t, in fact, have the infection?", "answer": 0}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nImportantly, the two new simplified forms of teixobactin have also proven to have identical potency against superbugs as the natural form of teixobactin.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nEach amino acid sits at a specific place in teixobactin's structure, and the Lincoln team has now successfully replaced enduracididine - which holds position ten - with two alternative amino acids which are not positively charged.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms. This omission is another reason the release should have made clear that although the researchers performed some laboratory tests for potential toxicity, teixobactin has not been tested in people, so its potential adverse effects are not known.", "answer": 0}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the researchers did not report adverse events in their journal article, they described at length how they excluded several categories of participants, including smokers, pregnant women, those with a family history of addiction, women with close relatives who had breast cancer, anyone under 40 and others, in order to minimize the potential risks of drinking alcohol. Other risks of alcohol include less common\u00a0events such as falls, which may not be apparent in a smaller study over only 2 years. In addition,\u00a0the public tends to generalize, and the take away from this story for some readers might be that red wine is good for everyone with diabetes. \u00a0In fact, this study was only among well controlled type 2 diabetics who were either on oral agents or insulin no more than once daily. The researchers explicitly warned about the potential risks of recommending that people with diabetes drink wine. That concern about harming people who might be vulnerable to adverse effects of alcohol was left out of the story.", "answer": 0}, {"article": "I was absolutely terrified because I saw my mom go through it, and I saw how much pain she was in,\" Barletta says.\nIn less than a week, she was starting back to her regular routine, including exercise.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\nIt was an absolute miracle.\"\nLaPook notes that it will be a few more years before this procedure is widely available.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There were no harms of treatment mentioned.", "answer": 0}, {"article": "U.S.-listed shares of Novartis closed up 1.2 percent .\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\nAfter 48 weeks of therapy, 84.5 percent of the 1,048 participants treated with Tremfya showed 90 percent improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70 percent on Novartis\u2019s Cosentyx, J&J said.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Since Tremfya is known to weaken the immune system, it places patients at an increased risk of bacterial, fungal, and viral infections.\nPeople taking this drug, and other immunosuppressives like it, must be screened for tuberculosis, since it could dramatically accelerate the disease.\nNone of this was mentioned.", "answer": 0}, {"article": "Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\nThe treatments that were compared and ranked included acetaminophen; ibuprofen; intra-articular (IA) or joint injections of cortisone; platelet-rich plasma (PRP); hyaluronic acid (HA); several NSAIDs, such as naproxen, celecoxib, and diclofenac; and both oral and IA placebo.\nAuthors analyzed 53 randomized controlled trials that examined knee OA treatments for at least 28 days and included a minimum of 30 participants per study group.\n\u2022 HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function.\nThis new research analyzed data from multiple trials to determine the relative effectiveness of various nonsurgical treatments for knee OA.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does refer to some potential harms of nonsteroidal anti-inflammatory drugs, including naproxen and ibuprofen. However, it does not quantify these risks and it does not address any of the potential harms of the other treatments in the analysis.", "answer": 0}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nThis data is notoriously hard to interpret, however, in part because it is based on women\u2019s self-reports: the public health message against drinking during pregnancy has been so widely adopted that women who do drink may significantly underreport their consumption to researchers.\n(More on Time.com: If I\u2019m Drunk, Then You Stepped On My Toes On Purpose)\n\nInterestingly, the new study parallels the effects of alcohol on health more generally; lighter drinkers tend to do better than teetotalers while the heaviest drinkers do worse.\nThe research included 11,513 children participating in a large U.K. study.\nWhatever the case, American health authorities remain united in their advice that no amount of alcohol is safe for the fetus during pregnancy \u2014 and anyone who is familiar with fetal alcohol syndrome knows why.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not put a number to the \"increased levels of behavior problems and lowered cognitive performance among children.\" It should have.", "answer": 0}, {"article": "Get the facts.\nThe study, published in the Pediatric Infectious Disease Journal, looked at the published data about effects from the vaccine and found that it has a \u201cfavorable safety profile.\u201d This study comes after many other previous studies that show essentially the same thing.\nThe Gardasil vaccine, on the other hand, caused some people to faint after getting it, and others got mild skin infections\u2014both of which occur somewhat rarely with other vaccines too, as you might expect.\nThere is no correlation between getting the Gardasil vaccine and seriously adverse effects such as \u201cautoimmune diseases (including Guillain-Barre Syndrome and multiple sclerosis), anaphylaxis, venous thromboembolism, and stroke.\u201d\n\nMind you, all these things and more have been used by people who attack vaccines as an argument against it.\nThis, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes the vaccine is not associated with serious adverse effects sometimes attributed to it (e.g. multiple sclerosis). It mentions that syncope and possibly skin rash are thought to be side effects of the vaccine.\u00a0Ideally, the story would have provided more information about how frequently these effects are seen (the main objective of the study being reported on).", "answer": 1}, {"article": "\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\nFriends thought Anne Schomaker was coping well with her loss, she recalled.\n\u201cI had terrible pangs of sadness and despondency.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\nI was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not come out and discuss the general topic of harms vs. benefits of \u201ccomplex\u201d therapy. But it does manage to clear our bar by quoting skeptic Jerome Wakefield, who says that labeling of people might result in over-treatment.\n\u201cBy diagnosing complicated grief just six months after a death, he said, \u201cyou\u2019ll get a lot of normal people receiving treatment they don\u2019t need,\u201d including drugs.\nWe\u2019ll give the benefit of the doubt here, although it\u2019s debatable whether a single quote about the controversy of labeling covers enough ground on this issue.", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a new study of middle-aged New Jersey men, taking cholesterol-lowering drugs was linked to a lower chance of dying from prostate cancer.\nMarcella\u2019s team didn\u2019t have the data to figure out if taking a statin for longer, or starting one earlier, was more beneficial than more limited use of the drugs.\nThe findings don\u2019t prove that the drugs, called statins, ward off aggressive cancer.\nBut they jibe with previous studies suggesting that getting cholesterol levels under control might help reduce the risk of life-threatening disease, researchers said.\n\u201cIf a person\u2019s on the fence about taking a statin medication for their heart, this is another potential benefit they may have by taking one of these,\u201d he told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job briefly mentioning statin side effects of muscle pain, nausea, gas, and liver dysfunction.", "answer": 1}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nWhat's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.\nBut experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.\nAfter four weeks, the trial found, the triple-drug therapy had improved lung function in patients with both types of mutations.\nThe trials were short-term, finding that the drug combinations improved adult patients' lung function over four weeks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported: \u201cSo far, the treatments appear safe. Most side effects in the four-week trials were \u2018mild to moderate,\u2019 the researchers said, and included cough, headache and increased sputum.\u201d\nThe story should also have said that three patients in the VX-445 trial discontinued treatment, due to severe adverse events including intestinal blockages intestines and temporary worsening of lung function. Another three had to temporarily stop treatment due to signs of liver damage, muscle weakness and constipation. Considering the small size of the trial overall, these numbers are important.", "answer": 0}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the AP and the NPR story we reviewed, this story at least provides a bit of information on the early trade off between angioplasty/stent and bypass surgery. \u201cResearchers found that at one year after the procedures, death rates were about the same for surgery and stents, reflecting the higher risk of mortality from the open-heart procedure itself\u2014about 2% for surgery compared with about 1% for stenting. The short-term risk of surgery can affect patients\u2019 treatment decision, especially given the prospect of open-heart surgery and weeks of recovery, compared with a less-invasive angioplasty.\u201d", "answer": 1}, {"article": "Breathing problems -- already a high risk because labor helps clear the baby's lungs of fluid -- happened four times as often in babies born at 37 weeks than those born at 39 weeks.\nAll of the women had previously had C-sections.\nOf those, more than 13,000 had elective C-sections.\n\"I think it points to a role for the baby in the initiation of labor and the baby's readiness to make the transition.\"\nThe findings from the study sponsored by the National Institute of Child Health and Human Development's Maternal Fetal Medicine Units Network also underscore the importance of a woman seeking medical care as early into her pregnancy as possible, so that doctors can accurately gauge the gestational age with an ultrasound, Mercer said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the harms of C-section.", "answer": 1}, {"article": "But study author Anna Giuliano believes that, \"vaccinating males would have a direct benefit that men would receive, as well as a community benefit.\nThis study involved more than 4,000 boys and men aged 16-to-26 from 18 different countries who were randomly assigned to get the vaccine or not.\n\"This well-designed study reinforces the idea that there is value in vaccinating young men against a virus that is nearly ubiquitous among sexually active individuals.\"\nAmong participants who completed the three-vaccine series, Gardasil afforded 90 percent protection against HPV.\nWEDNESDAY, Feb. 2, 2011 (HealthDay News) -- A large international trial finds that the Gardasil vaccine shields young men from human papillomavirus (HPV) as well as it protects young women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There wasn\u2019t a single mention of potential harm to any study participants, and there wasn\u2019t a sentence saying, \"Researchers did not find any significant harm for those who received the vaccine.\"\n In the broader social context, there was no mention of whether the vaccine might falsely lead young men to feel they are \"safe\" from a sexually transmitted disease, when the vaccine only covers four types of the human papillomavirus, and there are many more that are not covered.", "answer": 0}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\nThe researchers said the analysis in their study is better at forecasting how prostate cancer will advance compared to the current diagnostic tests being used for prostate cancer such as the prostate specific antigen test and the Gleason score.\nThese genes demonstrated the risk of the disease progression, which was more accurate than the currently used Gleason score test and PSA test.\nThis could lead to a better quality of life and more effective treatment based on which prostate cancer a man is diagnosed with.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The main potential harm from the test is risk misclassification (which could happen when the gene tests are applied in a larger, unselected population) resulting in either under- or over-treatment of prostate cancer. \u00a0This is not addressed in the news release.", "answer": 0}, {"article": "People with insomnia may have one or more sleep problems, including difficulty falling asleep, trouble staying asleep and difficulty getting back to sleep after waking in the night.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nThe drug also demonstrated superiority to placebo in the time it took to fall asleep and time spent awake after initially falling asleep, Merck said.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nIn the one-night measure, patients who took the highest dose of the Merck drug slept 12.2 percent more of the eight hours than those who got a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It mentions side effects, but it does not put any number to them. The press release, at least, notes that the incidence of these side effects was 3% or less, but, again, a little more context would be nice. And what about drug dependence? What about contraindications with other drugs, vitamins, foods? What about withdrawal problems? \nOne of the problems was drowsiness upon awakening. \u00a0Last time we checked, insomniacs don\u2019t need the help of a drug to achieve this result. \u00a0\u00a0It is unclear whether these adverse events are observed only during the active (pill taking) phase of the study or after. \u00a0It is also important that the effects of chronic use are not mentioned, and the reader will be interested in these (as the problem is chronic) and the harms may multiply over time. \u00a0Finally, because orexins, the brain chemical on which the drug is supposed to work, are involved in appetite and food-consumption, the occurrence of problems, or lack thereof, in this arena are particularly relevant and merit a mention.", "answer": 0}, {"article": ".\n\"Future studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy,\" said Cherian.\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\nRegister now for the 2018 AAN Annual Meeting Press Room in Los Angeles, April 21-27, 2018\n\nThe study was supported by the National Institute on Aging.\nThe AAN is dedicated to promoting the highest quality patient-centered neurologic care.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms. However, there are few (if any) harms associated with adopting a well-balanced diet that is high in fruits and vegetables. While it is always wise to consult a physician before making significant lifestyle changes, we feel that this is not necessarily something that a news release needs to state explicitly. With that in mind, we give this a satisfactory rating.", "answer": 1}, {"article": "But are they receiving it?\nWriting in the International Journal of Drug Policy, Lynn Kozlowski of the University at Buffalo and David Sweanor of the University of Ottawa point out that many websites omit information showing that products such as e-cigarettes, smokeless tobacco and snus are far less harmful than traditional cigarettes.\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\nA briefing posted on the site specifically states: \u201cCompared to tobacco products, electronic cigarettes are significantly safer.\u201d\n\nIn their paper, the researchers note that information on comparative risks is common for other products and activities, like over-the-counter medicines and even safety ratings of vehicles.\n\u201cThe public is dramatically misinformed about the relative risks of substitutable tobacco and nicotine products.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It is all well and good to say that smokeless products are far less lethal than cigarettes, but it behooves the news release to point out what, if any, drawbacks they may pose. But this release doesn\u2019t give us any actionable information to show why substitute tobacco products are safer. We are instead told,\nThe news release needs to tell readers what those risks are so they can make informed decisions about their own use \u2014 or not \u2014 of smokeless tobacco products. The CDC says the use of smokeless products:\nStill relatively new on the scene, but exploding in popularity, vaping delivers many unknown elements and chemicals to the lungs. Compared to Canada and the UK, the US severely lags in safety studies that compare harms from vaping and traditional tobacco products.", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nBaker said the researchers also saw a mild improvement in verbal memory in those treated with GHRH, but the results weren't as strong as for the executive function tasks.\nBaker said the researchers saw benefits in healthy adults and those with mild cognitive impairment who received GHRH.\nThe study medications were supplied by the manufacturer of the growth hormone-releasing hormone.\n\"Growth hormone-releasing hormone doesn't target one specific area in the body and brain,\" said study lead author Laura Baker, an associate professor of psychiatry and behavioral science at the University of Washington School of Medicine, in Seattle.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned spiked insulin levels.\u00a0 But it didn\u2019t mention any of the side effects reported in the study:\n\u201cAdverse events primarily consisted of local skin reactions (redness, itching, or stinging) and increased arthralgias. Other adverse events reported, although less frequently, included gastrointestinal upset, numbness or tingling in the hands, weight gain, and fluid retention. Although increased fluid retention can potentially precipitate or exacerbate symptoms of congestive heart failure and hypertension, coronary adverse events were not observed in our study.\u201d", "answer": 0}, {"article": "\"This makes it hard to follow up on patients.\"\nThe good news, according to a Brazilian study published by the journal PLoS One, is that two relatively simple measures can help to reduce the incidence of POCD: administering a small dose of the anti-inflammatory drug dexamethasone immediately before an operation and avoiding profound anesthesia during the operation.\nData from the scientific literature suggest a rise in mortality from POCD in the first year after surgery under general anesthesia.\nExcessively superficial anesthesia is known to incur a risk of patient recall of the procedure, which is undesirable.\nIn the fourth group (superficial anesthesia with dexamethasone), the incidence of POCD was 15.3% immediately after surgery, but after six months the pre-operative cognitive status was restored in all patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release refers in general to the risks inherent with both deep and superficial anesthesia, it does not mention any of the potential side effects associated with its recommended intervention, dexamethasone. And there is no shortage of information on dexamethasone available. According to the U.S. National Library of Medicine\u2019s Medline Plus page on dexamethasone, the drug\u2019s side effects range from vomiting to insomnia to depression. The page indicates that dexamethasone may also interact with a\u00a0 variety of other widely-used drugs. In addition, giving patients steroids, of which\u00a0dexamethasone is one, increases the risk of infection or worsening severity of existing infections. We don\u2019t expect a release to provide an exhaustive list of side effects, but acknowledging that there are known risks associated with the drug is important.", "answer": 0}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not explain harms.\u00a0However, diagnostic tests are only as good as their sensitivity and reliability, so it would have been good for readers to get an impression of whether the test catches every case of AR-V7, and the likelihood of false positives or false negatives. Even if that information is not yet available, it is important for readers to be made aware of the issue that a false result could lead to the wrong therapy being given.", "answer": 0}, {"article": "Type 2 diabetes, which is often tied to obesity, affects about 8 percent of the U.S. population, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nClinical trials are needed to investigate whether these beverages do indeed help prevent diabetes, the researchers say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of the potential harms of drinking large quantities of coffee and tea.\u00a0 There are always tradeoffs. This is worth at least a line. ", "answer": 0}, {"article": "\"We\u2019d like to see a bunch of lives saved, that\u2019s really the goal here,\" Quake said.\nHowever, a new blood test \u2014 which is still experimental and not yet available outside of a research lab \u2014 can pick up on gene activity in the body that suggests a pregnancy is at risk for preterm delivery, according to a study published Thursday in the journal Science .\nIn a test of 31 healthy pregnant women, testing for nine cfRNAs seemed roughly as accurate as an ultrasound at measuring gestational age.\nCurrently, gestational age is calculated in the first trimester using ultrasound, and it's not that accurate if used later in pregnancy.\nThe researchers also found a similar type of blood test could determine gestational age, which is used to calculate the due date of the baby.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Readers don\u2019t get a sense of what harms a false-positive test might expose a mother and her child too, and the rate here (nearly 17%) is rather high. Based on studies of the alternative test method \u2014 i.e. ultrasound \u2014 the risks of false-positive test/misdiagnosis include\u00a0high stress and anxiety, depression, expensive and unnecessary treatments, and other possible harms. (The most common interventions for increased risk of preterm birth include progesterone supplements and bedrest.)", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Along with failing to evaluate the evidence, the story completely skips the numbers attached to any harms. One study on the foam therapy does spell out the different side effects, although most of them appear minor. Perhaps most troubling to people looking mainly to get rid of unsightly veins is that 51 out of 166 people treated reported that their skin had changed color. So, perhaps, patients are trading one problem for another. It\u2019s information that, at a minimum, should be included. The story says, of the surgical approach, \u201cThe surgery can cause bleeding, bruising, nerve injuries, scarring and infection, and legs may have to be wrapped with bandages for several weeks.\u201d It needed to at least note some of the harms associated with the other approaches.", "answer": 0}, {"article": "\u201cOur lab is on an island in the South.\nNot everyone is convinced of the effectiveness of after-sun care.\nThe devotion to hats and rash guards, the careful selection of sunscreen and thorough application and reapplication every 90 minutes is at best tedious, and when children are involved, the process can be truly demoralizing.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\nI know that it\u2019s not realistic to say \u2018no sun.\u2019 \u201d\n\nShe is, however, quite knowledgeable about how to be safe when you\u2019re in the sun.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of any possible harms that could be caused by any of the products cited (including the potential harm of paying for something that doesn\u2019t work).", "answer": 0}, {"article": "Dr Gracia-Marco said: \"The sports we studied are the three most popular in the UK, and it's important to know what effects they have in relation to bone health.\nIn a study comparing adolescent footballers to swimmers, cyclists and a control group of boys not involved in regular sport, scientists at the University of Exeter found football led to significantly better bones after one year of training.\nDespite the many health benefits of cycling and swimming, the study found little difference in bone development between cyclists, swimmers and the control group.\nPlaying football can improve bone development in adolescent boys, new research shows.\nThough swimming and cycling have proven health benefits, the scientists said their study \"raises a question\" about whether they are good for bone development due to the non-weight bearing training - and they say young swimmers and cyclists could benefit from more weight-bearing exercise in training regimes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release included no discussion of the potential harms of playing soccer, especially in a highly competitive environment. In a 2010 report on soccer injury risks, the American Academy of Pediatrics noted that soccer \u201chas a higher injury rate than many contact/collision sports such as field hockey, rugby, basketball and (American) football.\u201d Lower leg and foot injuries are most common, and the rate of concussions is similar to those suffered by American football and hockey players.", "answer": 0}, {"article": "NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\n\u201cI believe it will have gradual uptake in the commercial setting given that this is a silent disease and existing therapies are pretty good,\u201d Schmidt said.\nAmgen last month applied for U.S. approval to market the drug for reduction of fractures and other skeletal-related problems in patients with advanced cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions an unpublished manufacturer-funded\u00a0safety study which purportedly found no side effects from one raspberry ketone product. However, it\u00a0emphasizes the\u00a0fact that neither the study author nor the funding company would provide a copy of the paper, suggesting that the results wouldn\u2019t hold up to scrutiny. The story also warns that people with\u00a0cardiac issues or high blood pressure should avoid these supplements, which may produce stimulant effects.\u00a0It could have mentioned that dietary supplements\u00a0are not well regulated, and\u00a0that many products \u2014 especially weight loss products \u2014 have been shown to contain undeclared drugs and other potentially dangerous ingredients.\n\u00a0", "answer": 1}, {"article": "Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health).\nResults obtained in preclinical studies in animals show that biologically active compounds present in both soy and cruciferous vegetables cause breast cancer cells to grow, but have opposite effects in animals that consume these compounds well before cancer is diagnosed and continue consuming them during and after cancer treatments.\nWASHINGTON -- Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.\nPhytochemicals, or bioactive food components, such as isoflavones in soy foods and glucosinolates in cruciferous vegetables may be the source of the benefit, researchers say.\nUntil more research is conducted, breast cancer patients should not suddenly start eating soy, if they have not consumed it before, says Leena Hilakivi-Clarke, PhD, a professor of oncology at Georgetown Lombardi and a co-author of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release responsibly devotes some attention to harms. It notes that in preclinical animal studies, \u201cbiologically active compounds present in both soy and cruciferous vegetables cause breast cancer cells to grow, but have opposite effects in animals that consume these compounds well before cancer is diagnosed and continue consuming them during and after cancer treatments.\u201d\nIt also cautions that breast cancer patients shouldn\u2019t start eating soy now if they haven\u2019t consumed it previously, noting that more research is needed to understand potential risks.\nNumerous studies have examined the impact of soy-based foods on women with breast cancer \u2014 with conflicting results \u2014 and we expect this debate will continue. Some recent studies suggest that eating soy, benefits women with breast cancer, particularly at the low rate it is consumed in the American diet.", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions re-operation due to infection and pain, mechanical failures and discomfort as harms of the implanted device.", "answer": 1}, {"article": "Baselga reports receiving honoraria from Roche; other co-authors report receiving speaking fees or honoraria from GlaxoSmithKline and fees from other drug companies.\nThat's the effect on overall survival in using the two-drug approach.\nThey looked to see which drug was better at eliminating invasive cancer in the breast and metastatic cells in the lymph nodes.\nAt that point, researchers evaluated who had better responses.\nThose given Tykerb alone had a 25 percent response.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was a high level description of possible side effects from these drugs.\u00a0 But no sense of the scope of these problems was provided.\nMore diarrhea?\u00a0 More frequent liver-enzyme alterations?\u00a0 Deaths have been reported?\nHow much more?\u00a0 How many deaths?\nIf you can quantify ill-described \u201cresponse,\u201d you can quantify the harms.", "answer": 0}, {"article": "\u201cWe need more information on how this works precisely in people before we can advise them to take anything,\u201d he said.\nIf Elysium Health were developing Basis as a drug, it would have to conduct clinical trials with humans to prove that it works, and the Food and Drug Administration would have to sign off on its scientific evidence before it could be sold as medicine.\nIndeed, one scientist not involved with Elysium questions the company\u2019s marketing pitch, saying there is too little information to know what Basis can do.\nBut as a supplement, Basis and similar products only have to be shown to be safe for humans to take, with labels that are not misleading.\nMany products in the supplement business are launched with questionable science, but Elysium said studies in mice show a clear connection between increased levels of this compound, called NAD, and improved health in older mice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story suggests that supplements such as\u00a0Basis \u201chave to be shown to be safe for humans to take\u201d prior to being sold, and the story does not mention any potential harms. This language will likely give readers a false sense of security. How can we be sure that a product is \u201csafe for humans to take\u201d if it\u2019s never been tested in humans? Even if we don\u2019t know what specific harms might occur with this supplement, the story could have referenced examples of previous supplements that passed regulatory muster but were subsequently shown to cause serious harm (e.g. ephedra). It could also have mentioned the harm to your wallet of spending $700 a year on an untested product.", "answer": 0}, {"article": "Boston, MA - Women who eat more high-fiber foods during adolescence and young adulthood--especially lots of fruits and vegetables--may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H.\nThe study will be published online February 1, 2016 in Pediatrics.\nThe greatest apparent benefit came from fruit and vegetable fiber.\nFarvid was supported by the Japan Pharmaceutical Manufacturers Association.\n\"This work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned but we wouldn\u2019t expect any in a release touting the benefits of a high fiber diet.", "answer": 2}, {"article": "An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nU.S. researchers say the technique certainly shows promise.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains the short term harms associated with the therapy, noting that there were no \u201cmajor complications\u201d and that eight of the 28 patients \u201chad temporary trouble breathing due to a partially collapsed lung, but all got better on their own within a week.\u201d\u00a0 It would help to provide further information about whether those collapsed lungs required additional monitoring or hospitalization days.", "answer": 1}, {"article": "This was not statistically different.\nAlthough warfarin costs a few dollars for a 30-day supply, its cost approaches that of the other anticoagulants when doctor visits for monitoring are factored in, Hallstrom says.\nThe study suggests most patients can have just aspirin without increasing the risk for venous thromboembolism, but doctors need to consider factors such as a patient's history of clots, obesity and ability to mobilize after surgery when determining the best measure for clot prevention, Hallstrom adds.\nOver three months, just 1.16 percent of aspirin patients developed a serious blood clot.\nA recent Canadian study looked at the issue, but the analysis had a caveat: Each of the more than 3,400 clinical trial patients received rivaroxaban the first five days after surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "\u201cGood old aspirin\u201d implies that aspirin is benign and without potential harms, which is not accurate, even if the harms of aspirin are typically less than those of anticoagulants. There are two potential harms that were examined: bleeding and formation of clot. \u00a0While the report notes that aspirin was \u201cnot inferior\u201d to other anticoagulants, it was silent on the incidence of bleeding.", "answer": 0}, {"article": "\"Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial\" is published October 10, 2017.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\nThey note that as neither treatment completely relieved pain, more research is needed into effective pain relief, especially for more severe pain.\nThe study included 154 children aged 5 to 17 years who underwent minor orthopedic surgery, such as keyhole surgery on joints, ligament and tendon repair, suture or hardware removal at London Health Sciences Centre in London, Ontario.\nThe study was conducted by researchers from London Health Sciences Centre, Schulich School of Medicine & Dentistry, Western University, London, Ontario; Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta; and Children's Hospital of Wisconsin, Milwaukee, Wisconsin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Side effects from the drugs were listed as nausea, vomiting, drowsiness, dizziness and constipation.", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news release issued by Genentech about the FDA\u2019s decision to grant priority review describes baloxavir marboxil\u2019s most common side effects: diarrhea, bronchitis, nausea and sinusitis. The news release also states that overall incidence of adverse events seen in patients taking baloxavir marboxil were lower than those seen in both the placebo group and the group taking Tamiflu.\nThe STAT News story does not mention any potential harms.", "answer": 0}, {"article": "For more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\nHowever, the data do begin to shed light on why babies born through vaginal birth may have fewer health risks than babies born by C-section.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\nThe biggest difference between babies born by scheduled and unscheduled C-section appeared in risk for Type 1 diabetes.\nSurprisingly, the data showed more health problems among babies born by planned C-section than among those delivered by emergency C-section or vaginal birth, even though the planned surgery is done under more controlled conditions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is a comparison of harms and it did a reasonable job of describing relatively slight differences between the study groups: planned C-sections, unplanned C-sections and vaginal deliveries.\nThe headline overstates what the story describes carefully. In the excerpt below, italics by editor.\n\u201cOver all, the differences between a scheduled C-section and an emergency C-section were slight. However, the data do begin to shed light on why babies born through vaginal birth may have fewer health risks than babies born by C-section.\nThe biggest difference between babies born by scheduled and unscheduled C-section appeared in risk for Type 1 diabetes. The results showed that babies born by planned C-section had a 35 percent higher risk of Type 1 diabetes compared with babies born by emergency C-section, after adjusting for differences among the mothers.\u201d\nAs noted above, the risk sounds much higher when given in relative terms, but since we\u2019ve already docked points for that concern above,we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "\"The concept is very simple,\" Lee said.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\nThe cargo is delivered by zapping the device with a small electrical charge that's barely felt by the patient.\nThe procedure is also non-invasive.\nThis cargo, when delivered using the chip, converts an adult cell from one type to another, said first author Daniel Gallego-Perez, an assistant professor of biomedical engineering and general surgery who also was a postdoctoral researcher in both Sen's and Lee's laboratories.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While we are told that the \u201cprocedure is non-invasive,\u201d and that \u201cthe cargo is delivered by zapping the device with a small electrical charge that\u2019s barely felt by the patient,\u201d this implies a safety that may not exist. The release should have described how well the \u201cpatients\u201d (in this case pigs and mice) tolerated the treatment and what types of problems they might have developed. More importantly, it should also have warned that this experiment in a small number of animals might not uncover problems that would occur when used in a large number of people.", "answer": 0}, {"article": "\"Wow!\"\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\nLisa Jarvis has more details on that at the Haystack blog.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes the CF Foundation president saying there were no significant side effects.\u00a0 But even the press release  reported some numbers for discontinuation rates and severe side effects, so we wish the blog had as well.  ", "answer": 0}, {"article": "Visit the Mayo Clinic News Network.\nHowever, it was unclear whether these drugs could be used safely in cancer patients until now.\nWhile twice-daily injections of low-molecular-weight heparin has been the traditional treatment of choice for cancer patients who suffer a venous clot, Dr. McBane notes that there are numerous limitations to this therapy.\nDr. McBane noted that cancer and cancer treatment can be associated with kidney injury, which can limit the drug's use further.\nDr. McBane says quality of life surveys, which were taken monthly throughout the six-month trial, showed that patients markedly preferred oral apixaban over injectable dalteparin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While a lot of emphasis was placed on potential benefits of apixaban, no harms were mentioned. The release talks about the limitations of the comparator but not apixaban. It certainly seems that there are fewer side effects from apixaban than heparin, particularly because there are no injection-related issues (such as bruising, pain and swelling) from the oral medication. Yet this does not mean that apixaban is completely harmless; like other anti-coagulant medications, one of the side effects is major bleeding which can quickly become dangerous if not treated. \nIn this study, patients receiving apixaban had fewer subsequent blood clots and didn\u2019t appear to have higher rates of bleeding \u2014 the main complication of any blood thinner. Several caveats should be mentioned: first, this was a relatively small trial and included a range of different cancers. Follow-up studies are needed to confirm these results in more patients across a range of different cancers. Second, though it wasn\u2019t statistically significant, more patients in the apixaban group had died at 6 months (15.9% vs. 10.6%). Future studies should examine this further.", "answer": 0}, {"article": "\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\nSaper says yoga likely works by strengthening core and lower back muscles and helping with mind-body relaxation.\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\n\"Yoga makes me think about my back and how I'm standing and if I'm standing properly, then I can function better.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story could have included some statement of potential harms from yoga. While it may seem that yoga is innocuous, that\u2019s not exactly the case: In a 2017 Cochrane review of 12 different research studies on yoga and chronic back pain, they included potential harms, including the risk of \u201cincreased back pain.\u201d", "answer": 0}, {"article": "A decision by the FDA is due by May 17.\nAimovig has the \u201cpotential to help fill treatment gaps in more difficult patient populations whose migraine has not been adequately managed with current therapies,\u201d Sean Harper, executive vice president of research and development at Amgen, said in a statement.\nAmgen said Aimovig trial patients also had statistically and clinically meaningful improvements in secondary trial goals including fewer monthly migraine days and better physical function.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nHe said previous studies excluded patients who had tried more than two other treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says \u201cno Aimovig patients stopped treatment due to side effects, while around 1 percent of placebo patients discontinued because of side effects.\u201d\nAlthough this is helpful information, it doesn\u2019t give any insight into what side effects did occur or how frequently. Just because patients didn\u2019t discontinue treatment, that\u2019s not an assurance that the drug didn\u2019t cause meaningful adverse effects.\nMoreover, the story should have cautioned that there are concerns about the long-term effects of this type of therapy \u2014 particularly risk of cardiovascular disease \u2014 which can\u2019t be assessed with a 12-week study. MedPageToday shed some light on those concerns in its coverage.", "answer": 0}, {"article": "For more information, please visit www.QuakerOats.com, www.Facebook.com/Quaker or follow us on Twitter @Quaker.\nNewly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\nAfter an analysis of the types of fiber in each cereal, the researchers suspected that the higher molecular viscosity of the beta-glucan in the instant oatmeal contributed to its satiating effect over the oat-based, cold cereal.\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\n\"The satiety benefits of instant oatmeal alone were important findings,\" remarked lead author Candida Rebello, MS, RD, of Pennington Biomedical Research Center at Louisiana State University.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Direct harm from consumption of these products isn\u2019t likely, so we\u2019ll rate this Not Applicable. However, the study itself does note that a bowl of Honey Nut Cheerios has a lot more sugar than unsweetened oatmeal. In fact, one serving had about 20 grams, which is nearly as much as some experts say women should eat in an entire day.", "answer": 2}, {"article": "And Owens says that people with medical conditions like ulcers, kidney problems, liver problems or bleeding disorders are more vulnerable, as are people who take blood-thinning drugs and NSAIDs.\nAnd while many medical groups recommend daily aspirin to lower heart disease risk, not all federal agencies agree.\nThese new recommendations aren't final, and are open to public comment.\nBut for pretty much everyone else, assessing actual heart disease risk in consultation with your doctor is crucial to deciding whether to take aspirin every day.\nIf people don't have a significantly increased risk of having a heart attack or stroke over the next decade, Nissen says, they may be \"causing more harm than benefit.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0article highlights the risks of taking aspirin daily, in particular the risk of bleeding. The article even brings in an independent source, Dr. Nissen, who discusses the bleeding risks. The story would have been stronger had it helped the reader/listener understand the likelihood of those harms, as the ubiquity of aspirin use in our culture may lead individuals to downplay the medicine\u2019s possible harms. However, the story does enough to clear our bar here.", "answer": 1}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No track record to discuss.", "answer": 2}, {"article": "SCOTTSDALE, Arizona - A migraine is much more than just a bad headache.\nThe U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura.\nWhile there is no cure, a new study published in Cephalalgia in March shows single-pulse transcranial magnetic stimulation is a new way to prevent migraine attacks.\nBased on the current study and prior studies in acute migraine attack treatment, sTMS not only helps to stop a migraine attack, but it also helps prevent them.\"\nThis data is clinically significant.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release establishes in the first paragraph that TMS is \u201ceasy-to-use\u2026noninvasive\u2026safe,\u201d but does not mention any side effects. These include worsening headaches, transient mood disturbances, and very rarely seizures. Importantly, given how new this treatment is, studies on potential long-term side effects are lacking at this time.\nThe procedure cannot be used in people who have metal in their head such as stents, aneurysm clips, metallic ear/eye devices, and bullet fragments.", "answer": 0}, {"article": "Menopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\nSanten and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\nA comprehensive review published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism focuses on current and future approaches to management of menopausal symptoms after breast cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned in the release. The only nod to harms was the recommendation that women who were treated with chemotherapy for breast cancer should not be treated with hormone therapy.", "answer": 0}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nByron Caughey, Ph.D., a senior investigator in NIAID\u2019s Laboratory of Persistent Viral Diseases, is available to comment on this study.\nThe test correctly excluded all the 31 controls and diagnosed both Parkinson\u2019s disease and dementia with Lewy bodies with 93 percent accuracy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion of how patients might be affected by earlier diagnosis. For example, do patients want to know whether they have one of these incurable diseases?\nAccording to the study, \u201cthe earlier the diagnosis, the earlier that any appropriately targeted therapies can be initiated before further tissue damage is done.\u201d But the news release doesn\u2019t explore that potential benefit.\nAlso, a 93 percent accuracy rate means 7 percent of patients will get a false result. According to the study, the test correctly identified those without the disease in all cases, which means the disease was not detected in some patients, which could give them a false assurance.\nThe release doesn\u2019t assess potential harms of taking spinal fluid samples, which though generally considered safe it is still an invasive test and can result in headache, back pain, bleeding, and increased skull pressure. The release states that researchers are attempting to come up with better tests for neurological diseases \u201cusing the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\u201d ", "answer": 0}, {"article": "Previously, no treatment was available for these patients.\"\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\nTwo patients treated with regorafenib had their tumor shrink to an undetectable level, according to the study.\nThis study tested regorafenib's effectiveness as a second-line therapy on 573 patients previously treated with sorafenib, 194 of whom were given a placebo.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states only that \u201cregorafenib was well-tolerated with manageable adverse events\u201d [emphasis added]. This is an example of the disconnect that can occur between language commonly used among researchers and language that people use in everyday life. For example, of the 374 patients who received regorafenib, seven had deaths that, according to the journal article, \u201cwere considered by the investigator to be related to study drug.\u201d Few members of the lay public would be likely to automatically assume that death is a manageable adverse event, even when talking about last-ditch medical treatments for advanced cancers. Other side effects that cropped up in the study, and which could significantly affect quality of life for patients, included hypertension, pain and swelling in the hands and feet, diarrhea and severe bleeding. Fatigue was also present as a side effect but the degree of fatigue is not mentioned. ", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release makes no mention of possible side effects related to the use of hydroxyurea. The NIH\u00a0notes that those risks include a drop in white cell count or platelet count and, in rare cases, a worsening of anemia. According to NIH, \u201cthose side effects usually go away if a person\u00a0stops taking the medication.\u201d There were other adverse events measured in the study that should have been described as well.", "answer": 0}, {"article": "While 2 percent of adults aged 45 to 54 have disabling hearing loss, the rate increases to 8.5 percent for adults aged 55 to 64.\nMED-EL expects that the SYNCHRONY EAS Hearing Implant System will be available in the coming months.\nUNC participated in the EAS System clinical trials and implanted the device in more patients than any other hearing center that participated.\n\u201cOn average, patients performed more than twice as well on tests of speech understanding with EAS than they did with their hearing aids preoperatively, which speaks to the benefits of this technology,\u201d Pillsbury said.\nSYNCHRONY EAS (Electric Acoustic Stimulation) Hearing Implant System, which is manufactured by Durham-based MED-EL Corporation, received FDA approval on September 16.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release has zero information about harms, actual or potential.", "answer": 0}, {"article": "The Lancet.\nThe clinical efficacy results reported today are from the JET8 Phase-III clinical study (3107) (the JET8 study).\nThe pre-specified primary endpoint was the amount of sleep time in the first two thirds of the night.\nThe call will also be archived on Vanda's website for a period of 30 days.\nThe conference call will be broadcast simultaneously on Vanda's website.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The end notes attached to the release describe potential harms in clear terms. ", "answer": 1}, {"article": "Researchers have two main theories on why light therapy works.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nThe researchers said enough clinical evidence now supports mental health professionals recommending light therapy as a treatment for depression.\nLight therapy is cheap, easy to use and comes with few side effects compared to medication such as antidepressants, said lead author Raymond Lam, a professor of psychiatry at the University of British Columbia.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The short story does not mention potential harms of light therapy., and it doesn\u2019t say there are few or none known. Either way, we would have liked the story to address the notion of harm\u00a0I [Editor\u2019s note: As pointed out by a commenter, the story does note that light therapy \u201ccomes with few side effects compared to medication such as antidepressants.\u201d That\u2019s more than we gave the story credit for initially, but we decided to keep the Not Satisfactory rating because the story does not say what any of those side effects are or how frequently they occur.]\nInterestingly, if you look at the table on adverse effects in the original study, it shows that close to 1/4 of those on light therapy experienced diarrhea. We can\u2019t exactly explain that strange finding but it was worth mentioning.", "answer": 0}, {"article": "Atrial fibrillation also increases the risk for dementia.\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\nHowever, the findings show that people with atrial fibrillation should start taking blood thinners as soon as possible after their diagnosis and continue to take the drugs, Friberg noted.\nDuring the study, more than 26,000 of the 440,000 participants, all with atrial fibrillation, were diagnosed with dementia.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "People stop taking these drugs for a reason, and some of those reasons might have to do with the side effects or adverse effects which can also include unstoppable bleeding. The story should have mentioned this. As the article indicates, \u201cpatients start on oral anticoagulation for stroke prevention but they stop after a few years at an alarmingly high rate.\u201d\u00a0 It would seem an important question to explore: why do approximately 15 percent of patients stop taking the drugs within the first year, and then 10 percent each year afterwards?", "answer": 0}, {"article": "\"We don't want to treat any man unnecessarily with that type of treatment.\nOverall, hormone therapy reduced the risk of dying from prostate cancer over 10 years from 8 percent to 4 percent, Jones said.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nThe hormone therapy started two months before radiation.\nFor patients with high-risk prostate cancer, using hormone therapy for just a short while is not effective, he added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms associated with male hormone therapy were listed.", "answer": 1}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As good as this story was, there was no direct discussion of harms, although the harm of inappropriate use should be clear.\u00a0 However, patients who undergo cardiac catheterization face well known risks including kidney damage and failure, damage to blood vessels in the groin, sometimes requiring surgery. There is also a risk of heart damage and risks associated with the antiplatelet drugs used to prevent blood clots from forming. All of these risks are balanced out by the benefit in the right patients.", "answer": 0}, {"article": "Philadelphia, PA, April 18, 2017 - In the past, all forms of metastatic prostate cancer have been considered incurable.\nThe authors proposed that this end point may serve as a first step toward establishing a curative paradigm.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nRegardless, the movement toward a curative paradigm is much needed and the investigators are to be congratulated for setting forth a paradigm that can be used to assess the possibility of cure in a reasonable period of time.\"\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention harms at all \u2013 except to say that the combo treatment was \u201cwell tolerated.\u201d Given that the patients received a combination of drugs, surgery and radiation treatment, there are a host of potential side effects. We don\u2019t expect a release like this one to provide an exhaustive list of those potential harms, but we do expect it to acknowledge possible side effects in some sort of meaningful way. \u00a0Readers have no way of knowing what \u201cwell tolerated\u201d means in the absence of more facts.\nGranted, the published study offered very little observation in the way of harms. But in the absence of such information we encourage news release authors and journalists to seek clarification since it\u2019s a key consideration for people considering treatment options.", "answer": 0}, {"article": "\"Throughout evolution, the opposite--energy deficiency--has been the problem.\nResearchers in the lab of Jun Wu, research assistant professor at the LSI, wanted to better understand cinnamaldehyde's action and determine whether it might be protective in humans, too.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\nTheir findings, which appear in the December issue of the journal Metabolism, indicated that cinnamaldehyde improves metabolic health by acting directly on fat cells, or adipocytes, inducing them to start burning energy through a process called thermogenesis.\nScientists had previously observed that cinnamaldehyde, an essential oil that gives cinnamon its flavor, appeared to protect mice against obesity and hyperglycemia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no specific harms mentioned, however a disclaimer is included in the news release that \u201cWu cautioned that further study is needed to determine how best to harness cinnamaldehyde\u2019s metabolic benefits without causing adverse side effects.\u201d\nConsuming too much cinnamon can cause mouth irritation. Some people are allergic to the spice.\u00a0 According to WebMD, cinnamon can interfere with some medications, including antibiotics, diabetes drugs, blood thinners and heart medicines.", "answer": 0}, {"article": "score of 0.9 or higher at the age of 50.\nscore just over 2.0 had an individual risk of dying from prostate cancer during the next 25 years of about 6 percent, the researchers found.\nThe higher the score at age 60, the greater the long-term risk of dying from prostate cancer, Dr. Vickers and his colleagues found.\nBut the score does put them in a higher-risk group of men who have more to gain from regular screening, he concluded.\nscore of 2.0 or higher at the age of 60, and most of them will not develop prostate cancer, said the study\u2019s lead author, Andrew Vickers, associate attending research methodologist at Memorial Sloan-Kettering.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harm that might occur by a man who stops screening at age 60 because his PSA level was low who might still go on to die from prostate cancer. \u00a0The story provided estimates of this.\u00a0\nWhile presenting interesting insights about prostate cancer risks, the story did not include any information about the accuracy of the PSA test itself. At the very least, it ought to have indicated that there are common factors that can increase an individual\u2019s PSA level which are unrelated to prostate cancer.", "answer": 0}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nThe integration of palliative care improves symptom control and decreases unwanted health care use, yet many patients are never offered these services.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\nConsultation with the palliative care team included establishment of goals of care, advance care plans using standardized communication protocols, transition planning and symptom assessment and treatment using the Edmonton Symptom Assessment Scale (ESAS).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to imagine many harms associated with a palliative care consultation. It might be helpful to point out that\u00a0patients who are recommended for that type of consultation are still free not to choose palliative care.", "answer": 2}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms discussed in the story. We can presume that faster surgery is safer, but whether hip repair is done rapidly or after three days, all surgical patients\u00a0are at risk of harm, and so the risks should be discussed.", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nJust because the system produced strong results in mice does not mean people will respond the same way.\nThe problem with existing alginates is that the body eventually catches on to the material as a foreign substance, suffocating the implant in a layer of scar tissue.\nPlus, donors are in short supply and can\u2019t yield enough cells to treat the millions of people with type 1 diabetes around the world.\nVegas said that if the primate studies are successful, the next step will be developing a therapy to be used in people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a nod in the direction of harms when it notes that there was a minimal immune system response to the transplanted cells. An immune response is currently one of the harms that limits the usefulness of this procedure.\nBut the story should have gone further to describe how the transplantation procedure is performed. This is an invasive approach that is not without risks and adverse effects.", "answer": 0}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nDoctors who did not perform the surgery won\u2019t have that context, which may explain part of the survival benefit of returning to the original hospital, he said.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\nIf these patients have complications weeks later, they end up going to a local hospital, not the one where they had surgery.\nAmbulance drivers and emergency department doctors should make every effort to get a patient who has had major surgery back to their original hospital, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of any downside that might be caused by returning patients requiring rehospitalization back to the hospital where the original work was done. It\u2019s conceivable that policies encouraging people to go back to their original hospital could delay treatment of problems that can get worse without immediate care. For example, if someone travels for a procedure, getting back to the hospital for readmission could take longer than going to a local hospital. The story does note that going to the original hospital often results in more timely care, but the flip side was worth mentioning, too.", "answer": 0}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nStill others, like Dr. Glick, are starting to tell women with estrogen-fed cancers that although they still need chemotherapy, they may not need the most intense treatment.\nIn many cases, it is patients who want the most aggressive treatment.\nFor women with breast cancer, of course, the uncertainty is excruciating.\nWhat if some women with estrogen-fed tumors do benefit from chemotherapy?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not provide enough information on the potential short-term and long-term harms of chemotherapy. There is only anecdotal evidence from one woman who developed nerve damage. Common short-term side effects of chemotherapy can include nausea and vomiting, hair loss, and fatigue. Younger women may also experience early menopause and infertility as a result of certain chemotherapy regimens. Potential, though more rare, long-term side effects are more serious and may include: bone disorders, heart problems, blood clots and nerve problems.", "answer": 0}, {"article": "If all it requires is to take a closer look at the images, how can we ignore it?,\" he said.\nBecause the study involved women who received both mammography and CT scan for clinical indications, these women may have been more likely than the average woman to have coexisting conditions, although Hecht said these were unrelated to heart disease.\n\"Even by the conservative estimate of 10 percent, approximately 4 million women nationwide undergoing screening mammography will exhibit breast arterial calcification; with 2 to 3 million of them likely to have signs of premature coronary atherosclerotic disease,\" the authors said.\nWhen researchers added 33 asymptomatic women with established CAD, breast arterial calcification was more powerful than both risk assessment formulas, which suggests the presence of subclinical atherosclerosis may be a more important indicator of heart disease than other risk factors.\nThere were even fewer false positives among younger patients; researchers said that if a younger woman had breast arterial calcification, there was an 83 percent chance she also had CAC.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release didn\u2019t acknowledge that false-positive scans can lead to additional expense, anxiety, further testing, and perhaps treatment with unnecessary medications that have unwanted side effects. Follow-up tests may also expose women to additional radiation.", "answer": 0}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\n\u201cThere are anywhere between 25,000 to 30,000 stillbirths a year in the United States.\u201d\n\nLockwood and Norwitz\u2019s support for induction at 39 weeks not only surprised many of the doctors at the session, it also upset those who believe less intervention is the safest route for mother and baby.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\n\u201cNature is a terrible obstetrician,\u201d he said, referring to the \u201ccontinuum\u201d of pregnancy and birth: the large number of zygotes that never implant, the 75 percent lost before 20 weeks, and stillbirth.\n\u201cSince we don\u2019t know exactly what triggers labor, why mess with it?\u201d\n\nHausman suggested learning from countries such as Denmark or Sweden, where midwifery is the first line of care and where fetal and maternal mortality rates are lower than in the United States.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes several opponents of earlier induced labor, who refer to risks including \u201cdecreased blood flow and oxygen to the baby,\u201d detached placenta and uterine wall tearing.\nWhile these harms are outlined in only vague and general terms, without specific numbers or citations, this at least acknowledges harms, so we\u2019ll rate as\u00a0Satisfactory.", "answer": 1}, {"article": "But plasma insulin response was sharply lower in fructose drinkers, which may affect what we eat, according to the senior author, Dr. Kathleen A.\n\u201cDon\u2019t stop eating fruit.\nPage said.\n\u201cNo,\u201d Dr.\n\u201cInsulin is released when we consume glucose,\u201d she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not Applicable for this story.", "answer": 2}, {"article": "New Rochelle, NY, June 19, 2017-A pilot feasibility study to determine if young children with autism spectrum disorder (ASD) and their parents would tolerate and adhere to an office- and home-based acupuncture/acupressure intervention showed completion of all 16 biweekly sessions and measurements of their effects before, during, and after the protocol.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\nA complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t discussed at all. To be clear, the risks here are low. As the Mayo Clinic notes, \u201cThe risks of acupuncture are low if you have a competent, certified acupuncture practitioner.\u201d But, then again, the release also doesn\u2019t mention the importance of finding a certified acupuncture practitioner. And even with certified practitioners, there are risks, from soreness and bruising to infections. In addition, individuals with bleeding disorders are not good candidates for acupuncture.", "answer": 0}, {"article": "\"Massage is an out-of-pocket cost,\" she said.\nAdditional investigation is needed to replicate the results of the initial study and to conduct a cost-benefit analysis of massage therapy, Munk said.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nThe study also looked at different characteristics associated with patients being more likely or less likely to experience clinically meaningful change from massage.\nMore than 50 percent of those who participated in the study experienced clinically meaningful improvements in their low back pain with disability, according to Munk.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We hesitate to suggest that any harm could come from a massage. But the release could have included a statement of there being \u201cno evidence of harms\u201d during the study, if that were the case.\nDepending on the cause of the back pain, is there a potential risk that some patients might experience a worsening of pain after a massage? The release doesn\u2019t say whether people with injuries should avoid massage and seek help from a back specialist. This is especially important if people are seeking therapy on their own, without seeing a physician.", "answer": 0}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health.\nThe latest outcomes measuring the impact of CDC\u2019s national tobacco education campaign are as strong as those achieved in its first year, and suggest that three years into the campaign, the ads were still having a significant impact.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\nThe website includes detailed assistance developed by the National Cancer Institute to support smokers trying to quit.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Intuitively, it may be hard to consider the possibility that there could be harms attributable to an anti-smoking campaign. However, some assessments of other public health education programs have found that to be the case, and we wish this summary had at least addressed the possibility.\nIn 2008, for example, ABC News reported on a large Congress-mandated study of the effectiveness of a $1 billion anti-drug campaign that launched in 1998. The report was published in the American Journal of Public Health.\n\u201cThe study\u2019s authors,\u201d ABC reported, \u201cassert that anti-drug ads may have unwittingly delivered the message that other kids were doing drugs, inadvertently slowing measured progress that was being made to curb marijuana use among teenagers.\u201d\n\u201cOverall, the campaign was successful in achieving a high level of exposure to its messages; however, there is no evidence to support the claim that this exposure affected youths\u2019 marijuana use as desired,\u201d the report said.\u201d", "answer": 0}, {"article": "\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nMany of the electrodes sit in or near memory areas, and the wait can take weeks in the hospital.\nThis approach \u2014 called direct neural recording, and piggybacking entirely on the clinical placement of the electrodes \u2014 has become the leading edge of research into the biology of human memory.\nThe preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable.\nIn a series of experiments, the researchers had patients memorize lists of words and later, after a distraction, asked them to freely recall as many of the words as they could.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that brain stimulation can weaken memory formation, and notes how brain implants require \u201ca delicate procedure\u201d to pull off. However, the risks of brain implant devices aren\u2019t discussed \u2014 and they\u2019re significant.\u00a0According to Johns Hopkins University, surgery to implant electrodes in the brain carries a number of risks, including bleeding in the brain, leaking of spinal fluid into the brain, infection stroke, and more. After surgery, brain implants can cause tingling in the face and limbs, problems with speech or vision, dizziness, and other side effects.", "answer": 0}, {"article": "For further information, please visit www.nucleix.com.\nIn particular, in the non-small-cell lung carcinoma group (n=162), the most prevalent type of lung cancer affecting about 85% of lung cancer patients, Lung EpiCheck was able to identify correctly approximately 70% of patients.\nIn the small cell lung cancer group (n=13), Lung EpiCheck was able to identify correctly 92% of the patients, with a sensitivity of 100% in the limited stage, and 86% at the extensive stage.\nTo date, there is no adequate screening process for the early detection of lung cancer, bringing 5-year survival rate to approximately 15%.\nThe Lung EpiCheck blood test detects changes in DNA methylation in 6 markers in cfDNA associated with lung cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion on the potential harms of the screening test. \u00a0False positives can result in invasive and potentially\u00a0dangerous procedures and false negatives can give a false sense of security, which can prevent or delay other interventions such as smoking cessation.\nThe potential for false positives and negatives are very high for this blood test, according to the results presented in the release:\nIn particular, in the non-small-cell lung carcinoma group (n=162), the most prevalent type of lung cancer affecting about 85% of lung cancer patients, Lung EpiCheck was able to identify correctly approximately 70% of patients. With a correct identification of 59% of stage I patients, 77% of stage II, 76% of stage III and 83% of stage IV patients.\nOf note, low dose\u00a0CT scanning for lung cancer has reported false-positive rate that is lower than the rate reported for this blood test \u2014 and yet according to recent real-world experience, it still returns some 2,749 false positives for every lung cancer death averted.", "answer": 0}, {"article": "\u201cBut this is a small study, a proof of concept.\nGenazzani said the results showed DHEA has potential, especially for those women who may have problems in taking more conventional HRT.\n\u201cWe must bear in mind that this is a pilot study with a small sample,\u201d Anna Fenton, co-editor of Climacteric, said in commentary on the work.\nItalian researchers writing in the journal of the International Menopause Society, Climacteric, said they had found the first robust evidence that low doses of DHEA can help sexual function and menopausal symptoms, suggesting it may one day become an alternative to hormone replacement therapy (HRT).\nBut they stressed that the trial was small, so far larger studies are needed to confirm the results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains the potential harms involved in taking hormone treatments, saying, \u201csales of HRT drugs have fallen sharply since a large study in 2002 found higher rates of ovarian cancer, breast cancer and strokes in women who took the pills, and the search has since been on for alternatives.\u201d But the story does not address any potential harms of DHEA, which was the subject of the story.\n\u00a0", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nEfficacy of Intrarosa, a once-daily vaginal insert, was established in two 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women, 40 to 80 years of age, who identified moderate to severe pain during sexual intercourse as their most bothersome symptom of VVA.\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\nIntrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Every intervention carries its own sets of risks. For Intrarosa, the most common side effects include vaginal discharge and an abnormal pap smear, according to the news release. But it doesn\u2019t detail what \u201cabnormal\u201d means or explain what the implications are for women who receive such a result. It also doesn\u2019t quantify the potential harms, including how many women experienced these adverse effects.\nFurthermore, the clinical trials cited in this release lasted for only 12 weeks, meaning long-term effects were not investigated. According to the US National Library of Medicine, the active ingredient DHEA may be unsafe if taken in high doses or long-term. Researchers also say DHEA may cause decreased breast size, a deep voice, increased genital size, irregular periods, oily skin and unnatural hair growth in women.\nSince the news release doesn\u2019t describe potential harms or talk about the drug\u2019s long-term effects, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "\"If the question were just, 'Does egg freezing and thawing work to achieve a pregnancy?'\nAnd yet, even Widra agrees that egg freezing has appeal if it can help avoid the anguish of infertility.\nStill, he says, freezing eggs offers many women the biggest game changer since the birth control pill 50 years ago.\nNow, technology is dangling the possibility that women can stop that clock, at least for a while.\nDr. Alan Copperman of Reproductive Medicine Associates of New York wastes no time laying out this harsh reality: By the time a woman hits her 40s, 90 percent of her eggs are abnormal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are risks of pre-term pregnancy because of in-vitro fertilization. There are risks to babies from being one of multiples \u2013 such as twins or triplets. These risks are just as important to discuss and weigh as the risks that the story puts forward as reason for this high-tech solution \u2013 having \u201cold\u201d eggs as a woman of 40 years. Yet the story does not discuss these.", "answer": 0}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any harms of treatment with Byetta.\u00a0 Every medication will have some potential side effects and these are not described.\u00a0 ", "answer": 0}, {"article": "In recent years, surgical techniques, anesthesia and other medical care advanced, and death rates fell.\nNot every older person can undergo such a difficult operation, he said but the great results seen in the new studies show that doctors have gotten good at figuring out who can.\nThe studies were reported at an American Heart Association conference this week in New Orleans.\nEven more impressive: 65 percent survived without any long-term complications \u2014 a \u201cvery, very remarkable\u201d result, Kurlansky said.\nOverall, 90 percent survived their surgery to leave the hospital.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story made short shrift of harms that might be associated with the treatment. \u00a0It mentioned that older patients want to decide for themselves whether to take the risk but then never detailed what risk was being alluded to. \u00a0The story also mentioned that 65% of the patients had no long term complications, but again \u2013 there was no discussion about what complications were seen to affect 35% of patients studied.", "answer": 0}, {"article": "Fat tissue has been linked to higher levels of damaging metabolic stress compounds, so losing weight and becoming more fit may create more hospitable conditions for sperm and improve its quality and volume.\nNow, researchers publishing in the journal have found that another lifestyle change\u2014exercise\u2014may also help improve sperm quality.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\nThere are already plenty of reasons to exercise, and now better quality sperm is one more worth noting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms in this story. Because one of the exercise interventions was high-intensity interval training (HIIT), a brief discussion of harms was needed (see safety concerns of this PDF).", "answer": 0}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nLarger studies in many more patients are needed before the drug will be available, though, she says.\nThe results really became clear when the researchers looked only at those patients with mild, early-stage disease.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\n\"While [beta-amyloid] is the leading hypothesis of what causes the disease, that has remained unproven.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story included more detail than the AP story about rates of chest pain, reporting that just over 1% of trial participants taking the active drug reported chest pain, compared to just 0.2% of those in the placebo group. We do take some issue with the description as chest pain when the report describes it as angina.\u00a0 However, this story did not mention the cases of brain swelling and or small bleeding in the brain that were included in the AP report. Nonetheless, we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nBut at our facility we think it makes caring for a patient much easier.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\n\"So we don't really know what it all means, and it's inappropriate to suggest that we could, based only on this compilation of data.\"\nAnd that has to be good.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The fact that the story could be entirely about surgically implanted devices and never acknowledge that surgery has risks or that the devices themselves have risks is odd, to say the least.", "answer": 0}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms found in the studyu of ustekinumab. ", "answer": 0}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nBecause the test comes with a small risk of a serious reaction, it should not be performed in very young children and pregnant women, among others.\nThe blood test is also part of a larger debate about who should be treating allergy sufferers.\n(And many sufferers of seasonal and pet allergies know what they\u2019re allergic to, so they don\u2019t need a diagnosis.)\nThe blood test, which is not without its own ouch factor, measures levels of circulating IgE.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only mentions one harm of the blood test \u2013 getting the blood drawn itself. The story should have mentioned other harms such as what happens with false positive or negative results or how the results may be misinterpreted by non-allergy specialist clinicians.", "answer": 0}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was really no mention of the harms of treatment other than that the combination medication studied failed to provide greater reduction of cardiovascular risk than from a statin alone. This is where reporting on unpublished data is troublesome.\u00a0 What harms surfaced in this trial? ", "answer": 0}, {"article": "\u201cThe question has been, \u2018What do you do with the rest?\u2019\u201d he says.\nSimilar to treatment with thalidomide, most of the patients had a relapse of their skin problems within weeks of stopping the drug.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nIn a small study from Spain, lupus patients showed dramatic improvements in skin lesions while taking the drug, lenalidomide (Revlimid), and most relapsed soon after they stopped taking it.\nThalidomide is best known as the drug that caused thousands of children to be born with missing limbs and other birth defects in the late 1950s and early 1960s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although not found in the current study (probably due to small sample size and short follow-up period), lenalidomide may lead to progression of full-blown lupus \u2013 and the story appropriately mentioned this. Birth defects were also mentioned as possible side effects of using lenalidomide.", "answer": 1}, {"article": "All rights reserved.\nCancer experts said the results need to be confirmed by another study before recommending multivitamins to the public.\nMost studies have been observational \u2014 they look at groups of people who do and do not use vitamins, a method that can't give firm conclusions.\nThere also was a trend toward fewer cancer deaths among multivitamin users, but the difference was so small it could have occurred by chance alone.\nFor every 1,000 men per year in the study, there were 17 cancers among multivitamin users and more than 18 among those taking the placebo pills.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that side effects were\u00a0similar between vitamin and placebo group participants, with the exception of their being\u00a0more rashes among vitamin users. The story also touches on potential harms from dietary supplements in general (e.g. they are minimally regulated\u00a0and not subject to\u00a0strict testing for purity) and for specific groups (e.g. people on blood thinners or with cancer, whose\u00a0vitamin use might interfere with their treatment).", "answer": 1}, {"article": "They had 68 percent fewer spine fractures and 40 percent fewer hip fractures than the study participants who got dummy shots.\nDr. Jacob Warman, an osteoporosis expert at Brooklyn Hospital Center, said denosumab might have potential as an add-on to existing drugs to boost results.\nDenosumab, an injection just under the skin, would have to compete against eight major types of pills and injected medicines, including estrogen and generic and brand-name Fosamax pills, long the market leader.\nDenosumab would be the first osteoporosis treatment that is such a monoclonal antibody \u2014 a type of immune cell cloned from the same parent cell to bind to a specific substance.\n\"Because this drug affects the immune system, the long-term effects on cancer risk or immune function is still unknown,\" she warned, saying she expects FDA will require Amgen to track risks over time if the drug is approved.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Citing the FDA\u2019s review of denosumab, as well as the adverse risks reported in the trials, the story mentions that this drug is associated with an increased risk of skin infections and some tumors.\u00a0 The story also points out that its long-term effects on cancer risk and the immune system are unknown. ", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms associated with this treatment were mentioned; only that it was \u201csafer\u2019 than \u201cwater pills\u201d (as opposed to the IV diuretic to which it was compared.) While no harms were mentioned, the article did mention that patients did not report feeling any better.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story does not clearly state the harms involved with either conventional therapy for osteoarthritis nor the injection of stem cells into the knee joint.", "answer": 0}, {"article": "\"You don't get back the time you lost at work or the time you lost with your children.\"\nBut about 80% will get relief, he says \u2014 defined as a headache reduction of at least 50% \u2014 after trying three or four drugs, alternative remedies and lifestyle changes.\nBut nearly 40% have headaches that are so frequent (at least once a week), severe or hard-to-treat that they qualify, Silberstein says.\nStudies find that just 3% to 13% use the treatments.\nFinding the right medication for the right patient can take a lot of trial and error and careful dosing, Silberstein says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story doesn\u2019t sugar coat the side effects of these drugs. A spokesman for a patient group notes that many patients \u201cspend months or years taking medicines that don\u2019t work and make them miserable.\u201d", "answer": 1}, {"article": "(That\u2019s a high dose; a 3 oz.\nBased on analysis of their blood samples, the people taking omega-3 supplements also showed lower levels of inflammatory markers, which suggests that the fish oil may be working by reducing inflammation following a heart attack.\nOne thing that has been less clear is what role fish oil plays in people who have already had a heart attack.\nThe effects remained strong even after the researchers accounted for the fact that all of the people were taking standard heart disease treatment drugs, including cholesterol-lowering statins and blood pressure medications.\nKwong says that the findings are only the first step toward considering whether omega-3 fatty acid supplements should be part of every emergency heart attack response.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms should have been included.\nAs made clear in a New York Times story, Dr. James Stein of the preventive cardiology department at the University of Wisconsin Hospital and Clinics explained that \u201cfish oil can be hazardous when combined with aspirin or other blood thinners.\u201d This seems particularly pertinent here as post heart-attack patients are often\u00a0recommended to take aspirin.", "answer": 0}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only potential harm mentioned with this medication is that it carries a safety warning about increased risk of heart attack and stroke associated with its use. \u00a0The story went on to discuss that salsalate carries this warning because of its drug class but that there isn\u2019t evidence demonstrating that these risks are associated with its use. \u00a0The would seem to be confusing \u2013 does this medication increase the risk of heart attack and stroke or not?\nFurther \u2013 because this drug has been around for a long time, \u00a0a lot is known about its side effect profile at least among people with arthritis.\u00a0 It would have been helpful to at least mention the known major side effects.\u00a0", "answer": 0}, {"article": "To learn more about inflammation and cancer, visit the U.S. National Cancer Institute.\nAs in other retrospective studies, he said, more research is needed to verify the potential link.\n\"Our study was performed retrospectively, using patient notes [from women] that had received treatment in the late 1980s and 1990s,\" Powe said.\nPrevious research, Lichtenfeld said, has found a reduced rate of skin cancer among men who take another type of blood pressure-lowering drug.\nPowe said he plans to do another study to validate the results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story offered no detailed discussion of side effects of beta blockers. While they are generally considered \"safe,\" the story didn\u2019t explain what \u2013 if anything \u2013 was observed, and it could have at\u00a0 least listed some of the more common side effects, including drowsiness, dizziness and weakness. ", "answer": 0}, {"article": "\"They are all extremely exciting and promising in animals,\" he said.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\nThe new study, which appears online Oct. 10 in the Archives of Neurology, is among the first to show the effects of an anti-amyloid drug in humans with Alzheimer's disease, but experts caution that while promising, more research is needed before this drug can be deemed safe or effective.\nThe hope is that gantenerumab or other drugs like it will not only prevent amyloid from accumulating in the brain, but also slow down the cognitive impairment that occurs in people with Alzheimer's disease, she added.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A strict application of this criterion warrants an unsatisfactory score.\u00a0 HealthDay only discussed \u201cpotential for serious side effects\u201d but didn\u2019t report how often they occured.\nWebMD, by comparison, gave specifics that two of six patients receiving the highest dose \u201cdeveloped possible findings of vasogenic edema, or fluid collecting in the brain tissue, as well as micro-hemorrhages.\u201d\nTo its partial credit, HealthDay did discuss several potential side effects, but why not report what was actually observed in the study you\u2019re reporting on?", "answer": 0}, {"article": "Traditionally, patients with leukemia, lymphoma and myeloma have first tried to find an adult bone marrow donor either from a close relative or from a national bone marrow registry.\nAlso, patients can get the treatment in about three weeks -- as opposed to six to eight for bone marrow from an adult donor, said Laughlin, founder and medical director of the Cleveland Cord Blood Center.\n\"That can be a critical time interval for a patient who is in remission,\" she said, noting that doctors often fear a patient's relapse while awaiting the transplant.\nCord blood transplants among unrelated donors have risen from 1 percent in 2001 to 24 percent last year, Laughlin says.\nAt that point, Mumford said, his choices were to continue chemotherapy and live for, maybe, another year and a half.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "See the larger discussion of the evidence evaluation.\nThe story mentions that the procedure has the same risks as adult bone marrow transplants, and that the procedure requires months of recovery. These risks aren\u2019t quantified \u2014 they\u2019re just \"well worth it,\" according to these two success stories.\u00a0The article makes the procedure seem like a no-brainer.\u00a0There are many other risks with these transplants, none of which are mentioned.\u00a0Detail about any of the risks, including the rates of death due to the procedure, are missing. As that reader who claims to be a transplant nurse, BMTnurse,\u00a0commented on the CNN\u00a0web page: \"Those whose transplants fail tend to die miserably.\"", "answer": 0}, {"article": "\"Once injected into a patient's artery, many stem cells are lost due to the combination of tissue blood flow, which can wash out stem cells, and cardiac contraction, which can squeeze out stem cells.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\nMarban and his wife, Linda, are founders of a company that has filed patents for the techniques.\nMarban and colleagues developed a technique in which they loaded cardiac stem cells with microscopic bits of iron.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of even potential harms \u2013 just how \"remarkably simple\" it could be to enhance treatment effectiveness.\u00a0 ", "answer": 0}, {"article": "Relatively few women at high risk of breast cancer take tamoxifen, and some patient advocates question whether they should, saying many women are exposed to side effects for each case of cancer prevented.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\nAs for the data on vaginal and vulvar cancer prevention, they came from combining data from three trials used to test the ability of the vaccine, Gardasil, made by Merck & Company, to prevent cervical cancer.\nThe new information presented here and published in the medical journal included a detailed analysis of the side effects of the drugs and the results of a survey of about 10 percent of the 19,747 women in the trial concerning their physical and mental well-being.\nBut raloxifene's edge in blood-clot and uterine-cancer avoidance was not statistically significant, and tamoxifen proved better at reducing the rate of noninvasive breast cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story lists the possible side effects and harms of the study medications, it does not mention how often these problems happened, nor how much they bothered women who had them. The article distorts the findings of the study by focusing on the quality of life data while downplaying or misrepresenting the data on outcomes for serious or life-threatening problems such as uterine cancer and blood clots. ", "answer": 0}, {"article": "Patients with Type-1 diabetes typically compensate by monitoring their blood sugar levels every few hours and injecting themselves with insulin as many as five times a day.\nEven if patients continue to require insulin shots, the treatment should be considered a success if it halts the destruction of beta cells, said Dr. Jay Skyler, with the Diabetes Research Institute at the University of Miami Miller School of Medicine, who wrote an editorial accompanying the study.\nAfter the stem cell treatment, \"patients are absolutely medication-free; they're off insulin,\" said Dr. Richard Burt, chief of the division of immunotherapy at Northwestern University's Feinberg School of Medicine and senior author of the study.\n\"We all realize that without addressing the problem at the level of the immune system, we'll never really beat Type-1 diabetes,\" said Dr. Francisco Prieto, who treats diabetics in Elk Grove, Calif., and wasn't involved in the study.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states the new treatment is not without risks and that patients are prone to infection.\u00a0 However, there is no description of how severe this harm might be (could lead to death) or how frequently these occurred in the study.\u00a0 So, although harms are briefly mentioned, they are not adequately developed or appreciated. This is not a minor issue, as stem cell transplant can be associated with very signficant risks of infection, organ failure and even death.\u00a0 \nAs an example of what can be left out in a shortened version, this line about potential harms appeared in the original LA\u00a0 Times story, but was left out of the Boston Globe version we reviewed: \"Burt's research group at Northwestern has performed 170 stem-cell transplants to treat a variety of immune system disorders, and two patients have died from the treatment.\"", "answer": 0}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of the drug.", "answer": 0}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\nA formerly controversial high-fat diet has proved highly effective in reducing seizures in children whose epilepsy does not respond to medication, British researchers are reporting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention any harms associated with the diet. In the particular study reported on, the side effects in the children studied included constipation, vomiting, lack of energy, and hunger. \u00a0In addition, there have been reports of more serious side effects occurring after longer term use of the diet.", "answer": 0}, {"article": "\"I could ride a bike!\nComprehensive statistics aren't available for the number of children with amputations, such as Wyatt.\nThere were other things the 12-year-old boy said he would do if he had two hands.\nEach electronic limb takes about 30 to 50 hours to make and assemble.\nFalardeau got in touch with the Orlando students through E-Nable , an online volunteer organization started by Rochester Institute of Technology research scientist Jon Schull to match people who have 3-D printers with children in need of hands and arms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of how well these 3D printed prosthetics fit onto the patient\u2019s bodies. Surveys of people with prosthetic arms indicate that many users have problems with skin irritation, blisters and upper body pain. This story did not mention any of the potential problems that are common among users of prosthetic limbs.", "answer": 0}, {"article": "Your skin clears up.\nRenowned weight loss surgeon, Dr. Mitchell Roslin said the short-term payoff is all in the science.\nHe warned that staying on the homemade diet long-term can carry health risks, which is why it's wise to speak with a doctor first before embarking on any plan.\nThe final diet was the three-week Quantum Wellness Cleanse, which Oprah Winfrey made famous.\nVolpe said she noticed results when her pants began getting baggy around her legs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms associated with these \u2018treatments\u2019 other than to mention that if you stay on a homemade diet long term (how long is long term?), it can carry health risks (such as? and how commonly?). \u00a0However this cautionary note is not sufficient for a consumer to have any concrete idea about what the risks are or how commonly they occur.", "answer": 0}, {"article": "Dr. Adolfo Llanos, a neonatologist at Nicklaus Children's Hospital in Miami, who was not involved with the new study, said the \"quality of this analysis is very good.\nWhen they do, the screening and treatments are not as good, Chen said, so blindness may be more likely.\nThe antioxidants in human milk may help, Chen said.\nAnd any breast-feeding appeared to reduce the odds of the serious eye disease by 46 percent, the research showed.\nAnd the risk of severe ROP seemed to be reduced by 90 percent, the researchers added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the framework of our criteria, the intervention in this study is the feeding\u00a0of human milk. The potential harms of human milk do not seem to warrant a discussion in this article however.", "answer": 2}, {"article": "Most recently, the F.D.A.\nBecause the compound is too big to cross the blood-brain barrier, the vaccine is expected to diminish or eliminate the pleasure associated with puffing a cigarette.\nPrevious NicVax trials were intended to assess vaccine safety and dosing levels rather than efficacy, but researchers reported high short-term rates of quitting.\nThe current study will test vaccine dosages and sequences of four or five shots; some subjects will get a placebo.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Early studies of NicVax looked at safety, yet we are given no information on adverse events from these early trials or on the potential harms of the vaccine. The story suggests that NicVax may be used in conjunction with other smoking cessation products, yet this has not been tested in clinical trials thus far.", "answer": 0}, {"article": "(Editing by Jon Loades-Carter)\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nThe drug\u2019s developers have since dropped the top dose from large ongoing Phase III trials.\nThe new study, which only involved 28 patients, is modest fillip.\nInvestor confidence in the antibody medicine, however, took a big hit in July 2008 when it failed to meet its main goal in a mid-stage trial and caused brain swelling at higher doses.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story stated:\u00a0 \"The treatment was generally well tolerated, although two patients on the highest dose had transient brain swelling. The drug\u2019s developers have since dropped the top dose from large ongoing Phase III trials.\"\u00a0 Well, what does generally well tolerated mean?\u00a0 And what\u2019s happening at the lower doses?\u00a0 This is confusingly incomplete.\u00a0", "answer": 0}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not adequately address potential adverse events and harms related to the Botox injections. The journalist offered a fairly standard list of Botox side-effects but then soft-pedaled by offering the reassuring viewpoint of a consultant for the manufacturer.\nThere is no mention that twice as many adverse events occurred in the Botox group than the placebo group in both clinical trials.\nAnd the story did not address the fact that long-term side-effects and adverse events may differ from those it describes. These clinical trials described adverse events that occurred over a matter of months. Yet those with chronic migraines might have Botox injections every 12 weeks for years and decades. It is possible that the number of adverse events might grow with increasing usage.", "answer": 0}, {"article": "That accounts for a small percentage of people.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nBy analyzing DNA collected through a saliva sample, the test detects increased risk of developing breast, ovarian or prostate cancer.\nThe test detects only three out of more than 1,000 known BRCA mutations.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are questions about accuracy that will be discussed under quality of evidence, but we think it\u2019s worth addressing potential harm associated with any screening test: false results. The Mayo Clinic notes that testing positive for a BRCA mutation can cause \u201cFeelings of anxiety, anger, sadness or depression\u201d; \u201cDifficult decisions about preventive measures that have long-term consequences\u201d; and \u201cFeelings of inevitability that you\u2019ll get cancer.\u201d Those are serious stresses associated with accurate diagnoses. Those same stresses can occur if someone is inaccurately told that they have a relevant gene mutation \u2014 and that\u2019s a potential harm that is worth mentioning.\nAnother potential harm is if a patient is found to have a \u201cVUS\u201d \u2013 variant of uncertain significance. This is an abnormality in the gene which may or may not be harmful. When patients undergo genetic testing under the care of their physician or genetic counselor, the possibility and implications of a VUS are explained prior to and after testing. As the 23andMe testing kit is available to the consumer without a prescription and without a requirement for pre-test education or counseling, patients may be further confused if the results reveal a VUS.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of \u201call\u201d birth control pills are noted, but no numbers provided. The story doesn\u2019t mention whether these harms happened to similar numbers of women in trials of the new pill. The story would have been more balanced if it had quoted an independent expert discussing the real or perceived potential harms.", "answer": 0}, {"article": "\"Nobody has the answer at this time,\" Perle said.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nReviewing 26 studies comparing spinal manipulative therapy (SMT) to other treatments such as medication, exercise or physical therapy, researchers from the Netherlands found that SMT appears to be no better or worse than other options at relieving back pain long-term.\nAn unrelated study of 401 patients with low back pain, published July 5 in Annals of Internal Medicine, suggested that massage may be better than medication or exercise for short-term pain relief.\nAbout two-thirds of the studies were not included in a previous review published in 2004, and all patients had suffered from lower back pain for 12 weeks or longer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any review of a treatment should discuss both the benefits and risks of the treatment. \u00a0The story focused entirely on the comparative effectiveness of manipulation, and ignored discussion of potential harms and adverse effects.\nMany people are scared away from spinal manipulation for low back pain over the potential risk of serious complications such as cauda equina syndrome, paralysis, and death\u2014or the exacerbation of a disc herniation. However, as the new systematic review pointed out, serious complications related to manipulation for low back pain are extremely rare.\n\n \n", "answer": 0}, {"article": "\u201cBut with these foods you do not consume the minerals, fluid and carbohydrates,\u201d he said, \u201cso nonalcoholic beer seems to be optimal\u201d for everything, perhaps, apart from your well-deserved celebratory carouse after the race.\n\u201cIncidence of upper respiratory tract infections was 3.25-fold lower\u201d in the nonalcoholic beer drinkers, the scientists reported, in the journal Medicine & Science in Sports & Exercise.\nThe men drinking the nonalcoholic beer reported far fewer illnesses than the runners swallowing the placebo beverage.\nThey also showed significantly less evidence of inflammation, as measured by various markers in their blood, and lower counts of white blood cells than the placebo group, an indication of overall better immune system health.\nThese effects matter, said Dr. Johannes Scherr, lead author of the study, because if a marathon runner\u2019s body is less sore and inflamed after a race, and he doesn\u2019t develop the sniffles, he can recover and return to training more quickly than he otherwise might have been able to.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the study, participants consumed 1-1.5 liters/day of non-alcoholic beer (or a placebo) for 5 weeks total.\u00a0There could be several potential adverse effects such as weight gain from extra calorie consumption, imbalances in nutrients if the liquid replaced other fluids, etc. No potential harms were mentioned.", "answer": 0}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of the potential harms of the new man-made bladder. ", "answer": 0}, {"article": "recommend.\u201d\n\nDr. Nestle finds the situation so confusing \u201cno rational person can possibly figure out how to make sense of it,\u201d she said.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\nFor those who eat more fish, both reports advise eating a variety of species to reduce the level of contaminants.\nreports to address the risks of mercury in tuna,\u201d said the consumer organization, \u201cwe are also concerned that both reports dismiss concerns about PCB\u2019s in most fish.\u201d\n\n\u201cThese reports are urging Americans to eat more seafood as if it were a crisis,\u201d Dr. Goldberg said.\nDr. Mozaffarian agreed that, because the evidence is based on observational studies and clinical trial data, it is not definitive, but he added, \u201cIt\u2019s the best evidence we have.\u201d As for the study\u2019s finding that total mortality could be cut by 17 percent, he said, \u201cWhile one can argue over the precise size of benefits, even if the benefit is only one-half or one-quarter as large, it still greatly outweighs the risk.\u201d\n\nThe report from the Institute of Medicine tells the government that much more research is needed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presents balanced information about potential harms of fish consumption, though it would have been stronger if it had included more detail about harms.\u00a0For example, it might have noted the effects of mercury on fetal development.", "answer": 1}, {"article": "The U.S. National Cancer Institute has more on prostate cancer.\nAspirin also comes with some risks of its own, including stomach bleeding, Choe pointed out.\n\"But we may expect to see this benefit in those who are taking aspirin for other [usually cardiovascular] reasons.\"\nA second study, conducted in the United States, Canada and Great Britain and also being presented at ASTRO, suggests that a combination of hormone therapy plus radiation may be the best treatment for men who have locally advanced prostate cancer with a high risk of returning.\nThis usurps the previous view that hormone therapy was useless or even \"unkind or toxic,\" said study lead author Dr. Malcolm Mason, a radiation oncologist with Cardiff University in Wales.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does mention that aspirin comes with risks, including stomach bleeding, so it might barely meet this criterion. However, the mild warning minimizes the risks in some frail or elderly individuals, where gastrointestinal bleeding can be lethal. The story left out a comment from the researcher that anticoagulants increase the potential for rectal bleeding in patients treated with radiation, which seems like an important consideration for men diagnosed with prostate cancer. Calling aspirin \"pedestrian\" in the first line is inadequate in the context of potential harms.\u00a0 There\u2019s nothing \"pedestrian\" about the catastrophic bleeding that may occur in some people.\u00a0 ", "answer": 0}, {"article": "Most head and neck cancers are linked to alcohol consumption and to smoking.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\nBut whether these substances actually protect against cancer in humans is a question for future studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If a story like this is going to promote the benefits of coffee, it should at least wink in the direction of possible harms of drinking 5 or more cups of coffee per day. This story didn\u2019t wink. ", "answer": 0}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Coffee does have adverse effects, such as insomnia, increasing anxiety, and triggering reflux in certain people. However, the story made no mention of coffee\u2019s downsides.", "answer": 0}, {"article": "But what about Alzheimer\u2019s?\nOne recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nDoctors have long said that an aspirin a day can help ward off heart attacks.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nOne of the most prominent followed more than 6,000 older women for nearly a decade and found that those who regularly took 100 milligrams of aspirin did no better on cognitive tests, over time, than those who were given a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only listed stomach bleeding and ulcers as side effects of aspirin.\u00a0 The story also failed to include information about often it occurs.\u00a0 However as this is a story about prevention of Alzheimer\u2019s disease, it should have mentioned that the bleeding risks associated with aspirin use increase with age.", "answer": 0}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\nThey also stress that women resuming their menstrual cycles does not mean the same thing as women preserving their fertility.\nThey conclude that using assisted reproductive technology \u2013 such as storing eggs before chemo, is \u201cthe most effective option for fertility preservation.\u201d\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The largest gap in this story is its failure to mention potential harms.\u00a0 In particular, it fails to mention the concern about potential adverse effects on disease outcome, a concern clearly stated in the editorial and in the original article.\n", "answer": 0}, {"article": "A message left for a spokesman for Ito En Inc. was not immediately returned last week.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nThe FDA previously has said that green tea likely does not reduce breast, prostate or any other type of cancer risk.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article reports that consumption of green tea is not an effective means for reducing risk of heart disease. However, it failed to mention potential harms of consuming green tea. It can be harmful for people with heart problems for whom consumption of caffeine is restricted. ", "answer": 0}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of possible harms of this experimental approach.\u00a0 In the study, there was a failure of detection in one instance because of normally occuring material which gave off the same light as the \"paint\".\u00a0 This would be an example of a false positive test; there may be other instances where something similar could occur. How often does this occur?\nThis is an example of an animal research report being presented as applicable to humans.\u00a0 There is little, if anything, known about potential harms in human subjects.", "answer": 0}, {"article": "Charli Scouller \n\nPR Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nc.scouller@qmul.ac.uk \n\nTel: 020 7882 7943\n\nQueen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 20,260 students from more than 150 countries.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nThe new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of potential harms from the new vaccine come from a study author who says, \u201cThis is a significant achievement. The new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\u201d \u00a0Indeed, the vaccine appears to be safe, but we think that a complete disclosure of the adverse events observed in the study would have been helpful.\u00a0The conclusion in the research notes, \u201cAdverse events related to injection site were more common in the 9vHPV group than in the qHPV group.\u201d So yes, the vaccine is safe, but appears to have more issues at the injection site than the existing vaccines. This is important because not all girls carry through with all three vaccinations; the lack of follow-through may be related to pain on injection.", "answer": 0}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThe only treatment is a bone-marrow transplant \u2014 if a compatible donor can be found \u2014 or a transplant with cord blood, if it was saved at birth.\nThey usually die within five years of diagnosis.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential adverse effects were not adequately addressed. The story did do a good job of highlighting concerns about gene therapies in general, pointing to problems that have cropped up in previous, unrelated gene therapy trials. And it mentioned that bone marrow transplants have risks. However, it didn\u2019t address potential harms associated with this study in particular. According to a supplement of the journal article, side effects ranged from fever and seizures to gastroenteritis. The side effects listed in the supplement also included those for one patient (2018), whose ALD symptoms worsened significantly after treatment began. It\u2019s not clear what effect, if any, the treatment had on the relevant patient.", "answer": 0}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a passing reference to harms. It says, \u201cLast week, following Boston media stories about migraine surgery, the headache society issued a warning: \u2018No convincing or definitive data show its long-term value,\u2019 it may cause irreversible side effects, and it can be \u2018extremely expensive.'\u201d It also lists some of the side effects seen in the small studies conducted by the surgeon who is the focus of the story. Given how serious the decision is to undergo surgery for a migraine headache, we think a much fuller discussion of side effects and harms was warranted, including quantifying what\u2019s been observed.", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story warns of overdiagnosis and overtreatment, and then specifically notes harms to \u201csexual function, urination and bowel movements.\u201d The story also quotes an expert who notes that \u201cthe way screening has been implemented in the United States leaves much to be desired\u201d and that the debate should be about \u201cwhether we can change our behavior so that it does more good than harm.\u201d\nHowever, while the headline and lead paragraphs focus on the claim that PSA screening saves lives, the first mention of overdiagnosis and overtreatment does not appear until more than halfway into the story.", "answer": 1}, {"article": "The incidence of shingles increases as we get older, because the body's natural immunity declines.\nThis is 12 times higher than other less effective shingles vaccines.\nParticipants in the trial received two doses of the vaccine, with the doses given two months apart.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\nLead researcher Professor Tony Cunningham from the Westmead Institute for Medical Research said the study shows that the vaccine stimulates production of a specific immune memory cell (CD4 T cells), generating a strong and sustained protection against the virus.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no information on harms. Most people had pain around the injection site, and a variety of other symptoms such as muscle plain, headache and nausea were reported during clinical trials.", "answer": 0}, {"article": "According to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\nPre-implantation genetic screening doesn\u2019t necessarily get patients pregnant unless they have good embryos, Robbins noted.\nExperts say the couples are not the only people who benefit from these tests.\n\u201cThey\u2019ve lost family members generation after generation after generation, or they\u2019ve had family members who\u2019ve suffered from chronic disease that\u2019s totally preventable.\u201d\n\nThese procedures not only help limit the passing on of diseases\u2014 they may also help couples get pregnant faster.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address potential harms. A 2011 article in the journal Nursing for Women\u2019s Health addresses the issue nicely: \u201cThe limitations of [preliminary genetic diagnosis] should be discussed with the couple, too. These include informing the couple about the possibility of misdiagnosis and also the possibility that genetic mutation-free embryos may not be identified.\u201d Those are risks that can\u2019t be overlooked.", "answer": 0}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\n\u201cAlthough this was not a randomized trial and there was no comparison group to assess whether specialized units performed better than nonspecialized (stroke) units, these (newly-reported) risks are substantially lower than expected.\nThe ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\nMore than two thirds of the patients in the study had a score of 4 or higher but the researchers caution that \u201climiting urgent assessment to patients with a score of 4 or more would miss approximately 20 percent of those with early recurrent strokes.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study doesn\u2019t appear to discuss harms or side effects from this newer type of specialized stroke care for TIA patients, nor does the story. However, that doesn\u2019t mean any exist. Aggressively treating\u00a0TIAs carries risks and side effects.", "answer": 0}, {"article": "The company\u2019s shares were up 30.9 percent at $18.84 after the bell on Thursday.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nThe long-acting therapy is taken once-daily at bedtime.\nAdamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\nThese patients have little recourse, other than opting for deep brain stimulation, a surgical procedure that involves blocking electrical signals from targeted areas in the brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the harms related to amantadine are mentioned in this release. One has to be especially cautious of the drug\u2019s effects on the central nervous system, including nervousness, anxiety, agitation, insomnia, difficulty in concentrating, and exacerbations of pre-existing seizure disorders.", "answer": 0}, {"article": "\"It's very difficult to get funding for studies on this topic,\" Harch said.\nOverall, there is relatively little research on hyperbaric treatment for brain injury, in part because pressurized oxygen can't be patented, which limits its potential profitability.\nFor the past 50 years, hyperbaric therapy has been approved by the Food and Drug Administration as a treatment for non-healing wounds, carbon monoxide poisoning, burns and decompression sickness.\nResearchers say it remains unclear how hyperbaric oxygen affects injured brains.\nMost of these are what are called mild traumatic brain injuries, or mTBIs \u2014 head injuries that don't cause a coma.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0 risks and complications of hyperbaric treatment are not mentioned.\nAccording to Johns Hopkins Health Library these risks include (but are not limited to) lung damage, middle ear trauma, visual changes, and seizures. Many of these are dose-related, which means that the risks increase with duration of therapy and degrees of pressurization.\nFurthermore, there are certain groups of people (like those with chronic lung, middle ear, sinus, or seizure disorders) who may not be good candidates.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention harms of transplant at all. Harms could include those from surgery itself, like problems with anesthesia, infection, and bleeding, and harms also include life-long effects of immunosuppresive therapy, which increase risk for infection, involve taking drugs every day for the rest of your life, and have other side effects. The story paints a very rosy picture of transplantation and is not balanced. One patient who is donating her kidney claims it\u2019s \u201cjust a 3 inch incision,\u201d which minimizes what\u2019s involved, especially for the donor. Often, donors have more pain post-operatively and a longer recovery period than the recipients. Plus, this quote minimizes other potential harms to the donor, such as what happens if her one remaining kidney fails? ", "answer": 0}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss potential harms. In a story like this, which is about a test that gives parents options, harm is a tricky concept and is very much in the eye of the beholder. Those who are likely to see a harm are those concerned about the slippery slope toward \"designer babies.\" Is there a moral and/or ethical question raised when parents can more easily conduct a test that might lead them to not have children? There is also the potential harm of falsely reassuring or alarming data.", "answer": 0}, {"article": "\"I know that I can just sort of be on my sits bones, instead of a funny arch with my stomach pushed out or my back arched in some strange way,\" says Rodriguez\n\nJosephine Gray is Rodriguez's teacher and is a certified instructor in Alexander Technique.\nBut there is evidence it can ease chronic low back pain over the long run.\nAfter a year, those who had massage were no better off.\nThose who had six Alexander lessons showed some improvement.\nBut finding a remedy for back pain can be a lot like a guessing game.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n3.\u00a0\u00a0\u00a0\u00a0 The article did not discuss harms or adverse events. The study did not report any adverse events related to Alexander Therapy. Individuals interested in this this treatment approach might find this information useful, since several other common therapies for chronic back pain\u2014from acupuncture to manual therapies to invasive treatments\u2014do cause adverse events and complications.\u00a0\n", "answer": 0}, {"article": "Unfortunately, condoms and vasectomy have remained the only commercially available contraception options for men.\nA new formulation currently being developed that contains half the amount of testosterone might decrease or eliminate that problem, Wang speculated.\nPreliminary findings suggest that when applied to the skin, the gel dramatically lowers sperm counts, thus also lowering -- though not eliminating -- the risk for pregnancy.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nAlthough men have sometimes received a bad rap for not being willing to assume responsibility for birth control, Dr. Joseph Alukal, an assistant professor of urology at NYU Langone Medical Center, in New York City, thinks this reputation may be somewhat undeserved.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions acne as one of the problems seen with men taking the hormone gel, adding that we \u201cjust don\u2019t know\u201d what the long-term side effects might be.\nWhile this comes close to meeting the standard, there are actually quite a few other known risks (some quite serious) associated with the administration of testosterone, which is one of the two hormones contained in the test gel. As the Mayo Clinic website explains, testosterone therapy may:\nThe story should have mentioned some of these risks.", "answer": 0}, {"article": "Older age and African-American race are risk factors for colon cancer, and there is evidence linking obesity and a sedentary lifestyle to the disease as well.\nBut they point to a need for further study into the different effects of HRT on specific organs, write the researchers, led by Dr. Katherine DeLellis Henderson of the City of Hope National Medical Center in Duarte, California.\nThe study, which followed nearly 57,000 California teachers, found that women who were using HRT at the outset were 36 percent less likely to develop colon cancer over the next decade than those who had never used HRT.\nHenderson\u2019s team also found that the beneficial effect of HRT was stronger among women who had had a first-degree relative diagnosed with colon cancer.\nWhile women who were current HRT users at the start of the study showed a lower risk of the disease, the same was not true of those who were former users.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did state, \"a large U.S. government study in 2002 found that postmenopausal women given HRT had higher risks of heart attack, stroke, breast cancer and blood clots than women given an inactive placebo.\"\u00a0 And we think that\u2019s sufficient in this case. ", "answer": 1}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nBecause this study was extremely small and presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal and confirmed in larger studies.\nThe cooling cap was, however, associated with an increased amount of slow-wave sleep -- or the deepest, restorative portion of sleep, the researchers reported.\nDr. William Kohler, medical director of the Florida Sleep Institute, said the concept was exciting and worth further research in larger studies that include body temperature measurements and brain imaging tests.\nThe cap is not yet available to consumers, although the lead researcher, Dr. Eric Nofzinger, has plans to bring it to market, Buysse said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of what would appear to be a question many people would have:\u00a0 didn\u2019t wearing a cap that is presumably connected to some water supply actually interfere with anyone\u2019s sleep? Did the control group patients wear a cap?\u00a0 If so, did it make it harder for them to sleep?", "answer": 0}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nIn memory tests, the people taking curcumin improved by 28 percent over the 18 months.\nFound in turmeric, curcumin has previously been shown to have anti-inflammatory and antioxidant properties in lab studies.\nThat study will include some people with mild depression so the scientists can explore whether curcumin also has antidepressant effects.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that four volunteers taking the curcumin supplement experienced abdominal pain and nausea \u2014 a potential harm of turmeric use. But the published study notes that six volunteers dropped out of the study due to \u201cgastrointestinal distress.\u201d This should have been noted in the release as well.\nAs we have reported before in our reviews related to health claims made about curcumin, the active ingredient of tumeric:\nNeither turmeric nor curcumin has been extensively studied in clinical trials, but\u00a0animal studies have shown\u00a0that chronic use could lead to stomach ulcers. In addition, the American Herbal Products Association classifies turmeric as a menstrual stimulant.\u00a0Turmeric should be avoided\u00a0in patients with bleeding disorders and bile duct obstruction.\nExperts believe tumeric is generally safe, although the quality of the available clinical studies is questionable.", "answer": 0}, {"article": "It also includes UCSF Health, which comprises three top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland, and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nThe researchers said that the Phase II results, published online on 10 October, 2017 in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.\nThe five-month Phase II trial enrolled 50 patients with relapsing but generally long-standing MS whose VEPs reflected preexisting deficits in neural transmission.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Most common side effects associated with clemastine include transient drowsiness, sedation, dizziness and disturbed coordination. Other adverse effects include rash, low blood pressure, vomiting, difficulty urinating and wheezing.\nParticipants did not experience serious adverse effects during the trial, according to the published journal article (page 5). Some patients experienced fatigue, which resulted in a patient modifying his/her dose, and a small number of patients showed increased levels of triglycerides, a type of fat found in blood.\nSince harms are not addressed in the news release, we rate it Not Satisfactory.", "answer": 0}, {"article": "A systematic review of C.B.T.\nImprovements like mine and those reported in the study bring sleep statistics for those with insomnia quite close to those without it.\nMy experience is consistent with these averages.\nMy sleep log also helped me be more objective.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no known harm to CBT for insomnia. There are myriad harms to commonly used sleeping medications. Although the story would have been strengthened by explaining those harms (further dissuading people from medication, which is what physicians recommend), the story\u2019s failure to mention harms of medications when the article itself was about CBT seems overly punitive. We\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention harms of either type of treatment. The researchers reported that about 1 in 10 people who received surgery had an intraoperative or postoperative complication, although few of these were serious. ", "answer": 0}, {"article": "\"I have to have a certain amount of interest in it because of my work.\"\nOne company, BioSante Pharmaceuticals, hopes to bring a testosterone gel to the market in 2012, but there aren't many other products on the horizon.\nThis was the second time a so-called \"female Viagra\" failed to make it on the market; in 2004, an FDA panel said no to Intrinsa, a testosterone patch meant to hormonally help women with a lack of desire for sex.\n\"There hasn't been much action in this area, and that certainly has to come up when a company is thinking about dumping money into researching a drug for female sexual dysfunction,\" says Phyllis Greenberger, president of the Society for Women's Health Research, which received money from Boehringer Ingelheim, the company that makes flibanserin.\nIn fact, for nearly all alternative practices there are no large-scale studies saying if they work or not.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is growing\u00a0recognition that many alternative treatments, despite being \"natural,\" can produce serious side effects. But this story doesn\u2019t even nod in the direction of harms, despite discussing approaches, including vaguely described \"herbal combinations,\" that\u00a0may carry unknown risks.\u00a0Notably, the FDA has repeatedly warned consumers against herbal dietary supplements marketed for sexual dysfunction, as these have been shown to contain Viagra or similar substances that can cause harm in some patients and can\u00a0interact uNPRedictably with other medications.", "answer": 0}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201cclinical trials have so far revealed no significant side effects\u201d from vaccine treatments.\u00a0However, we think the story should have included an important caveat: that these are early stage\u00a0trials involving small numbers of patients that\u00a0can\u2019t provide\u00a0conclusive evidence of safety. In addition, it should be recognized that addictions are\u00a0chronic conditions and these vaccine treatments are likely to be long-term as well. Therefore, longer-term adverse effects should be expected, especially for a treatment that interferes with molecules closely related to the body\u2019s natural chemical messengers. The story could have been a bit more circumspect on this point.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "All patients who undergo knee replacement operations have a small risk of complications (e.g. blood clots, infection, even death). Does the new gender-specific knee implant increase or reduce these or other potential harms? The article does not pose this question. At the moment, no one knows the answer. ", "answer": 0}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nStecker says if he had it to do over again, he would have waited for more research.\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\nStudying how the vascular system is involved in neurologic disease is an entirely new concept, Zivadinov says.\nMany desperate patients have spent their life savings flying overseas to have the procedure, only to have it fail a few months later.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions life-threatening blood clots are a risk of the procedure, and notes that people have died from the surgery. It also quotes an expert who calls the procedure \u201cunsafe.\u201d It would have been nice to have some statistics on adverse effects to help readers weigh these risks for themselves, but it may be too early in the game to expect this kind of systematic data.\u00a0At this point in the development of an experimental treatment, the priority for a story like this is to make sure potential harms are given adequate emphasis\u00a0\u2014 something this story accomplished\u00a0handily.", "answer": 1}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\n\"But it's also possible that the different dosing used in this study relative to previous work made a difference in the outcome.\nSUNDAY, Aug. 29, 2010 (HealthDay News) -- Most heart patients who take low-dose omega-3 fatty acid supplements don't appear to gain any additional protection against further cardiac trouble, new Dutch research cautions.\nAnd they're also not just looking at preventable fatalities but all heart-related events that follow.\nSo, the researchers theorized that the poor performance of the supplements may simply reflect the overwhelming power of the medications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0While mentioning that there didn\u2019t appear to be any benefit from the use of fortified margarine, the story neglected to report that there also didn\u2019t seem to be any overt harm from the used of the fortified margarine. Even the absence of harm is worth mentioning.\u00a0 We look for discussions of benefits, harms and costs in all stories and don\u2019t see same often enough. ", "answer": 0}, {"article": "Hill called the new research \"a call to action\" and added, \"we should be studying these policies.\nBut unlike opioids, marijuana has little addiction potential, and virtually no deaths from marijuana overdose have been reported in the United States, according to Bradford.\nAll of these states include chronic pain -- either directly or indirectly -- in the list of approved medical conditions for marijuana use, according to Bradford.\nThe details of the medical cannabis laws were found to have a significant impact on opioid prescription patterns, the researchers found.\nSince then, 29 states and the District of Columbia have approved some form of legalized cannabis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t explain that marijuana can be addictive and has side effects. These include an increased heart rate, which can increase the risk of a heart attack, especially in older people with heart problems. In some people, long-term use can cause intense nausea and vomiting. In addition, high doses of marijuana can cause psychosis, delusions or hallucinations. When smoked, marijuana can cause breathing problems and increase a person\u2019s risk of developing a lung infection.", "answer": 0}, {"article": "Characterized by the World Health Organization as a \"neglected tropical disease,\" leprosy (also known as Hansen's disease) is one of the most ancient diseases known to humankind and is caused by the bacteria Mycobacterium leprae.\nA viable vaccine to prevent and/or treat leprosy is the next step in the effort to bring this disease to an end.\n\"We believe this may be the most exciting breakthrough in leprosy treatment since multi-drug therapy, the current treatment for leprosy, was launched in the 1980s.\nReed, along with scientists from a variety of scientific organizations recently published \"Innovative tools and approaches to end the transmission of Mycobacterium leprae\" in , outlining what is needed to achieve this goal.\nWe look forward to this vaccine improving the health outcomes of people diagnosed with leprosy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The whole goal of a phase 1 trial is to determine what, if any, potential harms are associated with a given treatment. The release makes note of this, which is why we give it a satisfactory rating. That said, if animal trials turned up any potential harms that may be relevant to human subjects, those should have been mentioned here. And even if animal trials didn\u2019t turn up any potential harms, the release would have been stronger if it had mentioned that.", "answer": 1}, {"article": "\u201cShe sent me a picture of Giovanni playing in his front yard,\u201d Kefalis said.\nOne sign: Dr. Biffi is now head of the gene therapy program at Dana-Farber/Boston Children\u2019s Cancer and Blood Disorders Center.\nBut if you look closely, you\u2019ll see small memorials to one more: Liviana, who died in 2013 at the age of 5\u00bd of a rare, nightmare disease called late infantile metachromatic leukodystrophy.\nIt will take years to know for sure, but so far so good.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0mention of gene therapy\u2019s difficult past, including deaths in clinical trials, is valuable\u00a0context for the reader to understand the potential risks of experimental treatments, so we\u2019re glad the story mentioned that.\nHowever, there should have been some discussion of the potential harms of this new treatment. (If there are none, which is unlikely, that is also important and valuable information to the reader.)", "answer": 0}, {"article": "As rates of sugar-related disorders such as diabetes, obesity and heart disease climb, many experts believe that when Americans rid themselves of fat, they simply replaced it with sugar in all its forms.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\nThey\u2019re worried that the findings may shift attention away from what they consider to be the more fundamental issue \u2014 that overall, we\u2019re eating too much.\nThis study does hint however, at what might be happening.\nThat\u2019s the point.\u201d\n\nMORE: The Trouble With Sugar Free Kids\n\nNot everyone is convinced that the results definitely prove sugar, and not weight loss, is the culprit, however.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s\u00a0hard to say what \u201charms\u201d or risks would result from cutting sugar from childrens\u2019 diets. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nJust the reverse happens in children with autism.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\nNormal child development depends on interactions with parents and other people.\nWithout such interactions, language and social skills do not develop.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any potential harms in this story. It is very possible that the therapy itself does not have any actual side effects, but we always think the risk profile of a therapy is worth a mention.", "answer": 0}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\nHowever, those given a placebo also saw benefits, with 26.6% of participants in this group experiencing such a reduction.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\nIn half the patients treated, migraine duration was reduced at least by half.\nThe trial, called Strive, compared patients taking erenumab for six months with others given a non-active placebo dummy drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story teases us with the tidbit that erenumab may come with fewer side effects, yet not one of them or their potential frequency is established. The reported adverse event numbers are important: About 63% of the placebo group experienced at least one, compared to 55.5%-57.3% of the drug groups.", "answer": 0}, {"article": "Folic acid is naturally present in green, leafy vegetables and legumes.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\nMost of the population is thought to get adequate amounts for that reason.\nWhen all their grades from ten core classes were added up, there was a clear difference between teens who got the most and the least folic acid in their diets.\n\u201cThere is very little deficiency of folic acid in North America,\u201d Deborah O\u2019Connor, a nutrition researcher who was not involved in the study, told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 Harms not mentioned. The story could have mentioned the potential for excessive folic acid intake to interfere with vitamin B12 uptake which, though unlikely in a teen population, could mask symptoms of B12 deficiency. But we\u2019ll give it the benefit of the doubt on this.", "answer": 2}, {"article": "Dr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\nInfants who have a genetic profile linked with asthma risk could be protected against respiratory symptoms if they are breastfeed, according to a new study.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nWhen infants were not breastfed, those carriers exhibited a trend towards an increased risk of respiratory symptoms.\nFindings revealed that during the weeks that infants were breastfed, those carrying the asthma risk genotypes, had a 27% decreased relative risk of developing respiratory symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms associated with breastfeeding are admittedly few and far between. Infrequently, a mother may transfer environmental contaminants to a breastfeeding infant. However, the risks associated with genetic testing in general and the association between the\u00a0chromosomal variant\u00a0on chromosome 17, called 17q21, and the risk of the development of asthma are not covered. How reliable is the test?\u00a0 Is over- or under-diagnosis a risk factor? How likely is it that the child may eventually develop asthma? How many children with the variant develop asthma?", "answer": 0}, {"article": "Professor Babaeva said: \"Our findings suggest that the decreased rheumatoid arthritis disease activity with the combination of anticytokines translates into decreased cardiovascular risk.\nProfessor Babaeva's previous research showed that treatment with anticytokine drugs can decrease the activity of rheumatoid arthritis.\nThe current study investigated the impact of the combination of drugs on cardiovascular events.\nThe effect was more apparent and developed earlier when patients were treated with a combination of anti-TNF\u03b1 and anti-IFN?, both at extra-low doses.\nWe recommend this new approach for preventing cardiovascular events in patients with moderate disease activity who are not receiving the standard biologics and who do not have severe complications.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention of harms, and there are known rare, but serious, adverse effects associated with all of the biologic drugs used to treat rheumatoid arthritis.", "answer": 0}, {"article": "6 Kowdley KV, et al.\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does an adequate job, stating that the combination therapy \u201cwas well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\u201d It adds: \u201cThe most common side effects reported in 10% or more of patients were headache, fever, abdominal pain, diarrhea, vomiting, cough, fatigue, sore throat and nausea.\u201d\nBut one important caveat wasn\u2019t mentioned: Often negative effects aren\u2019t apparent until after a drug goes on the market and is used by a large and diverse population of patients. For example, if the drug resulted in a fatal complication in 2 out of 100 children, this small study could easily have missed that. It\u2019s risky to call a drug \u201csafe\u201d until it\u2019s been used in a very large number of patients.\nThis is particularly true when drugs are fast-tracked for approval by the FDA, as Harvoni\u2019s use in children is expected to be. As HealthNewsReview.org reported in January, Harvoni is among the new generation of hepatitis C drugs that are generating serious adverse effects that warrant further scrutiny. Hence, there could be unknown risks in extending this therapy to kids.", "answer": 1}]